NZ763267B2 - Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same - Google Patents
Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same Download PDFInfo
- Publication number
- NZ763267B2 NZ763267B2 NZ763267A NZ76326718A NZ763267B2 NZ 763267 B2 NZ763267 B2 NZ 763267B2 NZ 763267 A NZ763267 A NZ 763267A NZ 76326718 A NZ76326718 A NZ 76326718A NZ 763267 B2 NZ763267 B2 NZ 763267B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzopyranone
- carboxychloro
- difluorophenyl
- carboxy
- tnf
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 201000010099 disease Diseases 0.000 title claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 40
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 91
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical class C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 410
- -1 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone Chemical compound 0.000 claims description 175
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 129
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 201000004681 Psoriasis Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 206010040047 Sepsis Diseases 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 14
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 13
- MBUFGQWXDBCBSX-UHFFFAOYSA-N 2-oxo-3,4-dihydrochromene-3-carboxylic acid Chemical compound C1=CC=C2OC(=O)C(C(=O)O)CC2=C1 MBUFGQWXDBCBSX-UHFFFAOYSA-N 0.000 claims description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- 229960000485 methotrexate Drugs 0.000 claims description 9
- 201000008383 nephritis Diseases 0.000 claims description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- 206010061481 Renal injury Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000037806 kidney injury Diseases 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 8
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 208000025705 Axial Spondyloarthritis Diseases 0.000 claims description 7
- 208000009137 Behcet syndrome Diseases 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000004232 Enteritis Diseases 0.000 claims description 7
- 208000020402 Enthesitis-related juvenile idiopathic arthritis Diseases 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
- 201000005708 Granuloma Annulare Diseases 0.000 claims description 7
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 7
- 206010056969 Necrobiosis lipoidica diabeticorum Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 7
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 7
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 7
- 206010039710 Scleroderma Diseases 0.000 claims description 7
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
- 201000002661 Spondylitis Diseases 0.000 claims description 7
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 claims description 7
- 208000010265 Sweet syndrome Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 206010046851 Uveitis Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 7
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 7
- 201000001981 dermatomyositis Diseases 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 208000024908 graft versus host disease Diseases 0.000 claims description 7
- 208000002557 hidradenitis Diseases 0.000 claims description 7
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 7
- 230000000366 juvenile effect Effects 0.000 claims description 7
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 201000008043 necrobiosis lipoidica Diseases 0.000 claims description 7
- 230000003448 neutrophilic effect Effects 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 206010035116 pityriasis rubra pilaris Diseases 0.000 claims description 7
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 claims description 7
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 7
- 201000000306 sarcoidosis Diseases 0.000 claims description 7
- 230000036303 septic shock Effects 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 229960002964 adalimumab Drugs 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- UDXWSYOXIRPYFK-RRFJBIMHSA-N (4s)-3-[(2s,3s)-3-hydroxy-2-methyl-4-methylidenenonanoyl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CCCCCC(=C)[C@@H](O)[C@H](C)C(=O)N1[C@@H](C(C)C)COC1=O UDXWSYOXIRPYFK-RRFJBIMHSA-N 0.000 claims description 5
- 108010092160 Dactinomycin Proteins 0.000 claims description 5
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 5
- 229960000640 dactinomycin Drugs 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 239000004012 Tofacitinib Substances 0.000 claims description 4
- JMBINOWGIHWPJI-UNSOMVRXSA-N [(2r,3r,4r,5r,6r)-2-[[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@](O)(CO)CO2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O JMBINOWGIHWPJI-UNSOMVRXSA-N 0.000 claims description 4
- CZFNXFXZXWDYMZ-UHFFFAOYSA-N [5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxochromen-3-yl] hydrogen sulfate Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OS(O)(=O)=O)=C1 CZFNXFXZXWDYMZ-UHFFFAOYSA-N 0.000 claims description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims description 4
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 4
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003105 metformin Drugs 0.000 claims description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 229960003171 plicamycin Drugs 0.000 claims description 4
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 claims description 4
- 229960003712 propranolol Drugs 0.000 claims description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims description 4
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001350 tofacitinib Drugs 0.000 claims description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 2
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 claims description 2
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 claims description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 2
- QYGXVJHXZUSLQC-JEDNCBNOSA-N (2s)-2-amino-5-[(n'-methylcarbamimidoyl)amino]pentanoic acid;hydron;chloride Chemical compound Cl.CN=C(N)NCCC[C@H](N)C(O)=O QYGXVJHXZUSLQC-JEDNCBNOSA-N 0.000 claims description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- WQNDPVUOABHOHK-KBPBESRZSA-N (3s)-3-[[(2s)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)OC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F WQNDPVUOABHOHK-KBPBESRZSA-N 0.000 claims description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 claims description 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- DVGLBKDNVHDMTD-UHFFFAOYSA-O 2-[3-(n-(5-bromo-1-propylpyridin-1-ium-3-carbonyl)anilino)propanoylamino]ethyl 3,4-dihydro-1h-isoquinoline-2-carboxylate;nitrate Chemical compound [O-][N+]([O-])=O.CCC[N+]1=CC(Br)=CC(C(=O)N(CCC(=O)NCCOC(=O)N2CC3=CC=CC=C3CC2)C=2C=CC=CC=2)=C1 DVGLBKDNVHDMTD-UHFFFAOYSA-O 0.000 claims description 2
- IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims description 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 2
- MRRXPMZNBRXCPZ-UHFFFAOYSA-N 5-(3-methoxypropyl)-2-phenyl-n-[2-[6-(pyrrolidin-1-ylmethyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-1,3-thiazole-4-carboxamide Chemical compound COCCCC=1SC(C=2C=CC=CC=2)=NC=1C(=O)NC1=CC=CC=C1C(SC1=NC=2)=NC1=CC=2CN1CCCC1 MRRXPMZNBRXCPZ-UHFFFAOYSA-N 0.000 claims description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 claims description 2
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 claims description 2
- 241001061264 Astragalus Species 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims description 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims description 2
- FHRRLKBYXTXCLG-UHFFFAOYSA-N Bis-N-norgliovictin Natural products N1C(=O)C(SC)(CO)NC(=O)C1(SC)CC1=CC=CC=C1 FHRRLKBYXTXCLG-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- LWFDUMPGOAKHKC-UHFFFAOYSA-N C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 Chemical compound C1=CC=C2C=C(C(=O)C(C(O)=C3O)=O)C3=CC2=C1 LWFDUMPGOAKHKC-UHFFFAOYSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 2
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 2
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 claims description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- DNTSIBUQMRRYIU-UHFFFAOYSA-N GW 9662 Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C(=O)NC=2C=CC=CC=2)=C1 DNTSIBUQMRRYIU-UHFFFAOYSA-N 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 108010026389 Gramicidin Proteins 0.000 claims description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims description 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- DZKZCXUIXLRBSY-UHFFFAOYSA-N Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O Chemical compound Oc1ccc2oc(O)c(-c3ccccc3)c(=O)c2c1O DZKZCXUIXLRBSY-UHFFFAOYSA-N 0.000 claims description 2
- 108010016076 Octreotide Proteins 0.000 claims description 2
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002350 Procyanidin B2 Polymers 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 2
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- 102100037576 Sestrin-2 Human genes 0.000 claims description 2
- 101710186851 Sestrin-2 Proteins 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 2
- 244000166550 Strophanthus gratus Species 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 claims description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims description 2
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229960004420 aceclofenac Drugs 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims description 2
- 229930185474 acteoside Natural products 0.000 claims description 2
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims description 2
- 229960002459 alefacept Drugs 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- ORDAZKGHSNRHTD-UHFFFAOYSA-N alpha-Toxicarol Natural products O1C(C)(C)C=CC2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O ORDAZKGHSNRHTD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000528 amlodipine Drugs 0.000 claims description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims description 2
- 229960001164 apremilast Drugs 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000817 bazedoxifene Drugs 0.000 claims description 2
- 102000007379 beta-Arrestin 2 Human genes 0.000 claims description 2
- 108010032967 beta-Arrestin 2 Proteins 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 claims description 2
- 229960004272 bucillamine Drugs 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 235000004883 caffeic acid Nutrition 0.000 claims description 2
- 229940074360 caffeic acid Drugs 0.000 claims description 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 229960000530 carbenoxolone Drugs 0.000 claims description 2
- JYHHJVKGDCZCCL-UHFFFAOYSA-J carbon monoxide;dichlororuthenium Chemical compound [O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].Cl[Ru]Cl.Cl[Ru]Cl JYHHJVKGDCZCCL-UHFFFAOYSA-J 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960003184 carprofen Drugs 0.000 claims description 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims description 2
- 229960000590 celecoxib Drugs 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 2
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 229960003677 chloroquine Drugs 0.000 claims description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004588 cilostazol Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960002896 clonidine Drugs 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 229960003009 clopidogrel Drugs 0.000 claims description 2
- 229960001338 colchicine Drugs 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 235000007336 cyanidin Nutrition 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 claims description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 claims description 2
- GSZRULWGAWHHRI-UHFFFAOYSA-N deguelin Natural products O1C=CC(C)(C)C2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O GSZRULWGAWHHRI-UHFFFAOYSA-N 0.000 claims description 2
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 claims description 2
- 235000007242 delphinidin Nutrition 0.000 claims description 2
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960004590 diacerein Drugs 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 229950010033 ebselen Drugs 0.000 claims description 2
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 claims description 2
- 229960002694 emetine Drugs 0.000 claims description 2
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 claims description 2
- 229940002671 entocort Drugs 0.000 claims description 2
- 235000019126 equol Nutrition 0.000 claims description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 2
- BPSMYQFMCXXNPC-MFCPCZTFSA-N eritoran Chemical compound O[C@H]1[C@H](OCCCCCCCCCC)[C@@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](OCC[C@@H](CCCCCCC)OC)[C@H](OP(O)(O)=O)[C@@H](COC)O1 BPSMYQFMCXXNPC-MFCPCZTFSA-N 0.000 claims description 2
- 229950007107 eritoran Drugs 0.000 claims description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005542 ethidium bromide Drugs 0.000 claims description 2
- AQRXDPFOYJSPMP-QFIPXVFZSA-N ethyl (2s)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate Chemical compound C1=CC(S(=O)(=O)N(C)[C@@H](CC(C)C)C(=O)OCC)=CC=C1CN1C2=CC=NC=C2N=C1C AQRXDPFOYJSPMP-QFIPXVFZSA-N 0.000 claims description 2
- LEEIJTHMHDMWLJ-CQSZACIVSA-N ethyl (6r)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate Chemical compound CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC1=CC=C(F)C=C1Cl LEEIJTHMHDMWLJ-CQSZACIVSA-N 0.000 claims description 2
- 229940117360 ethyl pyruvate Drugs 0.000 claims description 2
- 229960005293 etodolac Drugs 0.000 claims description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960000192 felbinac Drugs 0.000 claims description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001395 fenbufen Drugs 0.000 claims description 2
- 229960001419 fenoprofen Drugs 0.000 claims description 2
- 235000011990 fisetin Nutrition 0.000 claims description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 2
- 229960002011 fludrocortisone Drugs 0.000 claims description 2
- 229960004369 flufenamic acid Drugs 0.000 claims description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 2
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000588 flunixin Drugs 0.000 claims description 2
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003883 furosemide Drugs 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 229950000501 gabexate Drugs 0.000 claims description 2
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960003627 gemfibrozil Drugs 0.000 claims description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 2
- 235000002780 gingerol Nutrition 0.000 claims description 2
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 2
- 229940025294 hemin Drugs 0.000 claims description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229940073062 imuran Drugs 0.000 claims description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 229960004187 indoprofen Drugs 0.000 claims description 2
- VVOXDJYPDCSQMI-UHFFFAOYSA-N inflachromene Chemical compound CC1(C)OC2=CC(O)=CC=C2C2C1=CCN(C1=O)N2C(=O)N1C1=CC=CC=C1 VVOXDJYPDCSQMI-UHFFFAOYSA-N 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229960005435 ixekizumab Drugs 0.000 claims description 2
- 235000008777 kaempferol Nutrition 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004384 ketorolac tromethamine Drugs 0.000 claims description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000681 leflunomide Drugs 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003768 lonazolac Drugs 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002373 loxoprofen Drugs 0.000 claims description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- 229960003464 mefenamic acid Drugs 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 claims description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004963 mesalazine Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
- 229960002237 metoprolol Drugs 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- 229960005485 mitobronitol Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229950000844 mizoribine Drugs 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000990 monobenzone Drugs 0.000 claims description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 2
- 235000007743 myricetin Nutrition 0.000 claims description 2
- 229940116852 myricetin Drugs 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001920 niclosamide Drugs 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 2
- 229960003343 ouabain Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- JMBINOWGIHWPJI-UHFFFAOYSA-N pedicularoside A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(COC2C(C(O)(CO)CO2)O)OC(OCCC=2C=C(O)C(O)=CC=2)C1O JMBINOWGIHWPJI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 229960001181 phenazopyridine Drugs 0.000 claims description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001289 prazosin Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- 229950010131 puromycin Drugs 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
- 229960000371 rofecoxib Drugs 0.000 claims description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 2
- 229950005741 rolipram Drugs 0.000 claims description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- 229960000953 salsalate Drugs 0.000 claims description 2
- 229950005789 sarpogrelate Drugs 0.000 claims description 2
- 229960004540 secukinumab Drugs 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- PLQRBFAACWRSKF-LJTMIZJLSA-M sodium;n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]carbamodithioate Chemical compound [Na+].[S-]C(=S)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PLQRBFAACWRSKF-LJTMIZJLSA-M 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960005559 sulforaphane Drugs 0.000 claims description 2
- 235000015487 sulforaphane Nutrition 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- 229960004492 suprofen Drugs 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 210000004233 talus Anatomy 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001693 terazosin Drugs 0.000 claims description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002372 tetracaine Drugs 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 239000004308 thiabendazole Substances 0.000 claims description 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 2
- 235000010296 thiabendazole Nutrition 0.000 claims description 2
- 229960004546 thiabendazole Drugs 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 229960001312 tiaprofenic acid Drugs 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005342 tranilast Drugs 0.000 claims description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- 229950008558 ulinastatin Drugs 0.000 claims description 2
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010088854 urinastatin Proteins 0.000 claims description 2
- 229960003824 ustekinumab Drugs 0.000 claims description 2
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims description 2
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 21
- 230000002018 overexpression Effects 0.000 claims 11
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 claims 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 19
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 432
- 150000001875 compounds Chemical class 0.000 description 254
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 225
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 124
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 108
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 78
- 238000001308 synthesis method Methods 0.000 description 75
- 230000015572 biosynthetic process Effects 0.000 description 74
- 238000003786 synthesis reaction Methods 0.000 description 74
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 65
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 229960000403 etanercept Drugs 0.000 description 16
- 108010008165 Etanercept Proteins 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 11
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 229960000074 biopharmaceutical Drugs 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- OYZWEOORLJBPMA-UHFFFAOYSA-N 3,5-difluorobenzoyl chloride Chemical compound FC1=CC(F)=CC(C(Cl)=O)=C1 OYZWEOORLJBPMA-UHFFFAOYSA-N 0.000 description 7
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 5
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical class ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YSULOORXQBDPCU-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethanehydrazonate;hydrochloride Chemical compound [Cl-].C[N+](C)(C)CC(=O)NN YSULOORXQBDPCU-UHFFFAOYSA-N 0.000 description 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 208000026326 Adult-onset Still disease Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010010164 Hypertension complications Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 102100026517 Lamin-B1 Human genes 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000010362 Protozoan Infections Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 108010052263 lamin B1 Proteins 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 201000011201 multicentric reticulohistiocytosis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012557 regeneration buffer Substances 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JPBOGNOGVSALOP-RQHBFRSESA-N (2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[(3S)-1-[6-[(3R)-3-[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoic acid hexahydrochloride Chemical compound Cl.Cl.Cl.Cl.Cl.Cl.CC(C)C[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](CS[C@@H]1CC(=O)N(CCCCCCN2C(=O)C[C@H](SC[C@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C2=O)C1=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JPBOGNOGVSALOP-RQHBFRSESA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UJCACMLMPLLRGW-UHFFFAOYSA-N 1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonic acid Chemical compound C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S(O)(=O)=O)=C2C UJCACMLMPLLRGW-UHFFFAOYSA-N 0.000 description 1
- RLRUKKDFNWXXRT-UHFFFAOYSA-N 2,5-difluorobenzoyl chloride Chemical compound FC1=CC=C(F)C(C(Cl)=O)=C1 RLRUKKDFNWXXRT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JUJUBIIKAIALTI-UHFFFAOYSA-N C(C)(=O)[ClH]C(C=1C(O)=CC=CC=1)=O Chemical compound C(C)(=O)[ClH]C(C=1C(O)=CC=CC=1)=O JUJUBIIKAIALTI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- POQBIDFFYCYHOB-UHFFFAOYSA-N Sarpogrelate hydrochloride Chemical compound Cl.COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 POQBIDFFYCYHOB-UHFFFAOYSA-N 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- LULXBAGMGMJJRW-UHFFFAOYSA-N n,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)CC(=O)N[Si](C)(C)C LULXBAGMGMJJRW-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011764 rheumatoid arthritis animal model Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient; and a method for treating TNF-related diseases, a reagent composition for inhibiting TNF and a method for inhibiting TNF, all of which use the same. The compositions can be orally administered so as not to cause injection side effects, do not cause immunological tolerance, and can effectively inhibit TNF activity by being directly bound to TNF while facilitating co-administering with a conventional oral preparation and dosage control.
Description
COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME Technical Field The present invention relates to a novel 4-benzopyranone compound derivative, and a composition for preventing, alleviating or treating TNF-related diseases, containing the same as an active ingredient, and a method for inhibiting a TNF activity by using the same.
Background Art TNF is a key inflammatory cytokine, and is attracting attention as a major cause of autoimmune inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, ankylosing spondylitis and the like. A variety of anti-TNF blockbuster biopharmaceuticals such as etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade) and the like are actively used as a therapeutic agent in a variety of TNF-related diseases including rheumatoid arthritis. Anti-TNF biopharmaceuticals show an excellent efficacy in a short period of time, but they are expensive and require repetitive injections, so patients are highly repulsed. In addition, about one third of patients have no therapeutic effect, and tolerance occurs within a few years due to immunological side effects even in patients who have responded to the drugs. There are obvious disadvantages such as difficulty of storage because it is necessary to store them at low temperature. Anti-TNF biopharmaceuticals have unmet medical demand.
As a strategy to overcome this, efforts have been made to find small molecular materials that can be orally administered and act like antibodies by being directly bound to cytokines or their receptors [He et al. (2005). Science 310(5750): 1022-1025]. However, binding to cytokines and their receptors occurs as a bond between protein and protein in a large area, and inhibiting the same by small molecular materials has not been effective so far.
An article regarding to a small molecular material that dissociates the TNF trimer by being directly bound to TNF has been published [He et al. (2005). Science 310(5750): 1022- 1025], a follow-up study seems to be stopped due to weak activity and the like. On the one hand, many small molecular material signaling inhibitors that block intracellular signaling are under development, and articles on the inhibitors of TNF expression or secretion that have unclear mechanisms have been published, but there is no data of in vivo activity. The development of small molecular material drugs that directly inhibit the binding between TNF and TNFR has not been successful so far.
Detailed Description of the Invention Technical Problem It is an object of the present invention to provide a novel compound which shows an excellent inhibitory effect on a TNF activity.
It is another object of the present invention to provide a pharmaceutical composition which can effectively prevent or treat diseases by showing an excellent inhibitory effect on a TNF activity.
It is still another object of the present invention to provide a health functional food composition which can effectively prevent or alleviate diseases by showing an excellent inhibitory effect on a TNF activity.
It is still another object of the present invention to provide a method for treating TNF- related diseases effectively.
It is still another object of the present invention to provide a reagent composition for inhibiting a TNF activity in vitro.
It is still another object of the present invention to provide a method for inhibiting a TNF activity in an animal excluding a human.
Solution to Problem In order to accomplish the object described above, the present invention provides a 4- benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof.
In order to accomplish another object described above, the present invention provides a pharmaceutical composition for preventing or treating TNF-related diseases, wherein the pharmaceutical composition contains a 4-benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient, and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF).
In order to accomplish still another object described above, the present invention provides a health functional food composition preventing or alleviating TNF-related diseases, wherein the health functional food composition contains a 4-benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient, and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF).
In order to accomplish still another object described above, the present invention provides a method for treating TNF-related diseases, comprising a step of treating with a 4- benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof in a pharmaceutically effective amount.
In order to accomplish still another object described above, the present invention provides a reagent composition for inhibiting a TNF activity in vitro, containing a 4- benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient.
In order to accomplish still another object described above, the present invention provides a method for inhibiting a TNF activity, comprising a step of treating an animal excluding a human with a 4-benzopyranone derivative represented by Formula 1 below, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof.
[Formula 1] in which, R is heteroaryl or substituted phenyl; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
Effect of Invention The present invention relates to a composition for preventing or treating TNF-related diseases, containing a 4-benzopyranone derivative compound as an active ingredient. The conventional protein TNF-inhibiting biopharmaceuticals are inconvenient for the administration in combination with other compound therapeutic agents, and can not be utilized for the development of a combination product. However, the TNF-inhibiting compound provided by the present invention is very easy to be administered in combination with other conventional compound therapeutic agents or to be utilized for the development of a combination product, and, in addition, has advantages such as excellent efficacy, low cost, non- invasive oral administration, non-immunogenicity, needlessness of refrigeration storage and the like, and thus, can be usefully utilized in a composition for preventing or treating TNF- related diseases.
Brief Description of Drawings Fig. 1 is a graph showing the TNF-inhibiting ability of representative compounds inhibiting TNF (the compound of Example 46, the compound of Example 61, and the compound of Example 51) among the small molecular compounds synthesized in one example of the present invention depending on concentration.
Fig. 2 shows the competitive inhibitory activity against TNF direct binding and TNF- etanercept binding of the compounds of the present invention ((a): the results of confirming the binding of the compound of Example 61 with TNF bound to chips by the surface plasmon resonance analysis method (Biacore T200), (b): the results of measuring the binding affinity (K ) of the compound of Example 61 with TNF bound to chips, (c): the results of measuring whether the compound binds to a TNF receptor, etanercept by the surface plasmon resonance analysis method, (d) the results of measuring the binding affinity (K ) of the compound of Example 30 for TNF which has a weak TNF-inhibiting efficacy as a control group, and (e): the results of confirming the inhibiting ability of the compound of Example 61 on the TNF- etanercept binding by the surface plasmon resonance analysis method).
Fig. 3 shows (a) the inhibitory activity against the binding between TNF-cell of the TNF-inhibiting compounds, and (b) the inhibitory activity against a TNF-induced signaling of the compound of Example 61 according to one example of the present invention.
Fig. 4 shows the sepsis therapeutic effect of the TNF-inhibiting compound according to one example of the present invention ((a): the results of measuring the in vivo TNF- inhibitory activity of the compound of Example 61 in a TNF-induced sepsis lethality model, and (b): the results of experimenting the in vivo efficacy on the administration of a TNF- inhibiting compound, the compound of Example 61 in combination with an ILinhibiting compound, LMT-28 using the lipopolysaccharide (LPS)-induced sepsis model).
Fig. 5 shows the effect of preventing or treating rheumatoid arthritis of the TNF- inhibiting compound according to one example of the present invention ((a): the results of confirming the effect of preventing rheumatoid arthritis of the compound of Example 61 in a TNF-overexpressing mouse model, (b): the results of confirming the effect of treating rheumatoid arthritis of the compound of Example 61 in a TNF-overexpressing mouse model, and (c): the results of confirming the effect of treating rheumatoid arthritis of the compound of Example 61 in a CIA mouse model).
Fig. 6 shows the therapeutic effect when co-administering the compounds in an animal model of dextran sulfate sodium (DSS) induced inflammatory bowel disease.
Fig. 7 shows the effect of protecting acute kidney injury of the compounds in an animal model of cecal ligation and puncture (CLP)-induced sepsis.
Fig. 8 shows the results of confirming the synergistic therapeutic effect when co- administering the compound of Example 61 and methotrexate (MTX) in an animal model of rheumatoid arthritis.
Best Embodiment for Working the Invention Hereinafter, the present invention will be described in more detail.
The present invention provides a 4-benzopyranone derivative characterized by being represented by Formula 1, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof: in which, R is heteroaryl or substituted phenyl; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
In one example of the present invention, a 4-benzopyranone derivative having a carboxy group at the 3-position as described above among the 4-benzopyranone compounds can be prepared through the method disclosed in Reaction Scheme 1 below.
[Reaction Scheme 1] A step of preparing the compound (3) by reacting the compound (2) with an acid chloride in the presence of a base and a catalyst (Step 1); a step of preparing the compound (4) by reacting the compound (3) prepared in Step 1 above through the intermolecular Wittig reaction (Step 2); and a step of preparing the compound (5) by de-esterifying the compound (4) prepared in Step 2 above under an acidic condition to remove the tertiary butyl group (Step 3).
Each preparation step of the present invention will be described specifically as follows: Step 1 is a step of preparing the compound (3) by reacting the compound (2) with heteroaromatic or benzoyl chloride in the presence of a base and a catalyst.
N,N-diisopropylethylamine, triethylamine, or pyridine may be used as the base, and 4- dimethylaminopyridine may be used as the catalyst. The acid chloride is used in a slight excess amount, preferably 1.05 equivalents, to result in the esterification reaction. It is possible to remove the acid chloride remaining after the reaction by the purification using chromatography or the reaction work-up method using a Girard-T (H NNHCOCH N(CH ) Cl) reagent instead 2 2 3 3 of chromatography. The acid chloride may be removed easily because the acid chloride reacts with the above Girard-T reagent to form a hydrazine derivative which is dissolved in water, and only the desired compound (3) remains in the organic layer, and all of the remains are contained in the aqueous layer.
The compound (2), which is the starting material of Step 1, may be obtained by reacting an O-acetylsalicylic acid chloride compound with a tertiary butoxy carbonyl methylene triphenylphosphorane compound in the presence of a reaction solvent of benzene or tetrahydrofuran and a catalyst of N,O-bistrimethylsilyl acetamide to prepare a phosphorane compound, and then, by removing an acetyl group through a deacetylation reaction using a base of dimethylamine, methylamine, or ammonia and a reaction solvent of tetrahydrofuran, methanol, or ethanol.
Next, Step 2 is a step of preparing the compound (4) by reacting the compound (3) prepared in Step 1 above through the intermolecular Wittig reaction. In this regard, benzene, toluene, xylene, or mesitylene may be used as a reaction solvent, and it is preferable to reflux with heating at 80 to 140 ºC for 8 to 24 hours.
Next, Step 3 is a step of preparing the compound (5) by de-esterifying the compound (4) prepared in Step 2 above under an acidic condition to remove the tertiary butyl group. The de-esterification reaction may be carried out by reacting the compound with trifluoracetic acid in a carbon dichloride solvent. By the reaction, the tertiary butyl group may be removed from the carboxylic acid butyl ester compound (4) to obtain the 4-benzopyranone compound (5) having a carboxy group at the 3-position in Formula 1.
In addition to the compounds specified as the base material, the solvent, and the catalyst in each of the above-mentioned reactions, a compound capable of promoting the reaction may be used as a base material, a solvent, and a catalyst.
The products after the completion of each reaction or all reactions as decribed above may be separated and purified by a customary work-up method, for example, chromatography or recrystallization.
The compound of Formula 1 of the present invention can be synthesized by using the synthesis methods described above and can be obtained by all customary methods, and commercially available reagents can be also used.
The 4-benzopyranone compound of the present invention may be in the form of a pharmaceutically acceptable salt thereof. The salt includes the customary acid addition salts used in the field of compound inhibitors, for example, salts derived from inorganic acids such as hydrochloric acid, bromic acid, sulfuric acid, sulfamic acid, phosphoric acid, or nitric acid, and salts derived from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, citric acid, maleic acid, malonic acid, methanesulfonic acid, tartaric acid, malic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, oxalic acid, or trifluoroacetic acid. In addition, the salt includes salts derived from metals such as, for example, lithium, sodium, potassium, magnesium, or calcium in the form of customary metal salts. The acid addition salts or metal salts may be prepared according to customary methods known in the field of organic chemistry.
In addition, the 4-benzopyranone compound of the present invention may be in the form of a solvate thereof. The term "solvate" means a complex or aggregate formed by one or more solute molecules, i.e., a compound of Formula 1 or a pharmaceutically acceptable salt thereof, and one or more solvent molecules. The solvate may be, for example, a complex or aggregate formed with water, methanol, ethanol, isopropanol, or acetic acid.
In addition, the 4-benzopyranone compound of the present invention may be in the form of a stereoisomer thereof. The stereoisomer includes all stereoisomers such as enantiomers and diastereomers. The compound may be a stereoisomerically pure form or a mixture of one or more stereoisomers, for example, a racemic mixture. The separation of certain stereoisomers can be carried out by any one of customary methods known in the art.
Specifically, in Formula 1 above, R may be furanyl, thiophenyl, or substituted phenyl 3 4 5 6 7 8 9 10 11 represented by , and R , R , R , R , R , R , R , R , and R may be each independently hydrogen, chloro, bromo, fluoro, or methoxy.
More specifically, the 4-benzopyranone derivative may be selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethyl-(4H)benzopyranone; 2-(2-furanyl)carboxymethyl- (4H)benzopyranone; 2-(2-furanyl)carboxymethyl-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(3- methylphenyl)carboxy-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2- (3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-methylphenyl) carboxymethyl-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H)benzopyranone; 2-(3- methylphenyl)carboxychloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxy chloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxybromo-(4H) benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxy chloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H) benzopyranone; 2-(3-fluorophenyl)carboxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3- fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy chloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxybromo-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy methyl-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4- chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
In one example of the present invention, the 4-benzopyranone derivative compound may inhibit a TNF activity by being directly bound to tumor necrosis factor (TNF).
Furthermore, the present invention provides a pharmaceutical composition for preventing or treating TNF-related diseases or a health functional food composition for preventing or alleviating TNF-related diseases, wherein the composition contains a 4- benzopyranone derivative represented by Formula 1, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient, and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF): in which, R is heteroaryl or substituted phenyl; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
Specifically, in Formula 1 above, R may be furanyl, thiophenyl, or substituted phenyl 3 4 5 6 7 8 9 10 11 represented by , and R , R , R , R , R , R , R , R , and R may be each independently hydrogen, chloro, bromo, fluoro, or methoxy.
More specifically, the 4-benzopyranone derivative may be selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethyl-(4H)benzopyranone; 2-(2-furanyl)carboxymethyl- (4H)benzopyranone; 2-(2-furanyl)carboxymethyl-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(3- methylphenyl)carboxy-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2- (3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-methylphenyl) carboxymethyl-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H)benzopyranone; 2-(3- methylphenyl)carboxychloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxy chloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxybromo-(4H) benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxy chloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H) benzopyranone; 2-(3-fluorophenyl)carboxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3- fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy chloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxybromo-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy methyl-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4- chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
In this regard, the TNF-related disease may be any one selected from the group consisting of autoimmune diseases, inflammatory diseases, cardiovascular diseases, metabolic diseases, immune disorders, neurological diseases, ophthalmic diseases, skin diseases, not limited thereto. psychiatric diseases, infectious diseases, and cancers, but is Specifically, the TNF-related disease may be any one selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, polymyalgia rheumatica, multiple sclerosis, thyroiditis, delayed hypersensitivity, allergy, contact dermatitis, atopic dermatitis, systemic lupus erythematosus, systemic sclerosis, adult-onset Still's disease, asthma, autoimmune thyroid disorder, Sjogren's syndrome, Kawasaki disease, pancreatitis, nephritis, hepatitis, pneumonia, chronic obstructive pulmonary disease, otitis media, angioplasia nephritis, myelodysplastic syndrome, osteoarthritis, sarcoidosis, granuloma annulare, Wegener's granulomatosis, lupus, hemolytic uremic syndrome, arteriosclerosis, vasculitis, heart failure, stroke, myocardial infarction, myocardial ischemia-reperfusion injury, sexual dysfunction, obesity, hypertension, diabetes mellitus and diabetic complication, hyperlipidemia, preeclampsia, kidney disease, liver disease, kidney injury, liver injury, snake bite, allograft rejection, organ transplantation, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, pain, central nervous system disease, uveitis, Behcet's disease, diabetic macular edema, macular degeneration, orbitopathy, glaucoma, hidradenitis suppurativa, multicentric reticulohistiocytosis, pityriasis rubra pilaris, eosinophilic fascilitis, panniculitis, necrobiosis lipoidica diabeticorum, cicatricial pemphigoid, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, toxic epidermal necrolysis, pustular dermatitis, dermatomyositis, polymyositis, bullous dermatosis, erythema nodosum, alopecia, depressive disorder, bipolar disorder, anxiety disorder, tuberculosis, viral infection, bacterial infection, fungal infection, protozoan infection, cerebral malaria, sepsis, septic shock, prostate cancer, skin cancer, colorectal cancer, kidney cancer, pancreatic cancer, ovarian cancer, breast cancer, bladder cancer, prostate cancer, lymphoma, glioma, osteosarcoma, leukemia, multiple myeloma, and cachexia, but is not limited thereto.
In one example of the present invention, the composition may further contain a drug, wherein the administration in combination with the drug can more effectively prevent, alleviate, or treat TNF-related diseases.
The "drug" used in the present invention is a substance capable of inducing a desired biological or pharmacological effect by promoting or inhibiting a physiological function in the body of an animal or human, and means a chemical or biological substance or compound suitable to be administered to an animal or human, and may (1) have a prophylactic effect on the organism by the prevention of undesired biological effects such as the prevention of infection, (2) ameliorate the condition caused by the disease, for example, mitigate the pain or infection resulting from the disease, and (3) play a role in mitigating, reducing, or completely eliminating the disease from the organism.
Specifically, the drug may be selected from anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antimetabolites, anti-inflammatory agents, antibiotics, signaling/enzyme inhibitors, receptor inhibitors, HMGB1 inhibitors, antithrombotic drugs, autophagy agonists, cytokine inhibitors, HMG-CoA reductase inhibitors, antihypertensive agents, anticancer agents, immune activation agents, B cell inhibitors, and T cell inhibitors, but is not limited thereto.
More specifically, the drug may be selected from the group consisting of methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, bucillamine, cyclosporine, tacrolimus, azathioprine, cyclophosphamide, mizoribine, penicillamine, oral gold preparation, antimalarial agent, 6-mercaptopurine, indomethacin, naproxen, sulindac, diclofenac, aceclofenac, mefenamic acid, aspirin, fenoprofen, salsalate, piroxicam, etodolac, flurbiprofen, ibuprofen, loxoprofen, nabumetone, lonazolac, meloxicam, fenbufen, ketorolac tromethamine, indoprofen, ketoprofen, suprofen, carprofen, tiaprofenic acid, flufenamic acid, ebselen, felbinac, tolmetin, flunixin, celecoxib, rofecoxib, hydrocortisone, cortisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, fludrocortisone, entocort, 5-aminosalicylate, 6- thioguanine, cytarabine, 5-fluorouracil, dacarbazine, mechlorethamine, thiotepa, chlorambucil, melphalan, carmustine, lomustine, busulfan, sestrin 2, withaferin A, celastrol, quercetin, luteolin, curcumin, metformin, dibromomannitol, GR270773, pentoxifylline, N-acetylcysteine, melatonin, resveratrol, mesalamine, single chain fatty acid, glutamine, gemfibrozil, retinoid, hydroxyurea, trihydroxyisoflavone, deoxykaempferol, kaempferol, gingerol, caffeic acid, cyanidin, cryptotanshinone, deguelin, delphinidin, equol, fisetin, myricetin, procyanidin B2, metronidazole, ciprofloxacin, niclosamide, thiabendazole, imipenem-cilastatin, fluoroquinolone, tofacitinib, glyburide, rolipram, doxycycline, VX-166, zVAD, L1, ISO- 1, tauroursodeoxycholic acid, HK-156, A-285222, CP-0127, Bis-N-norgliovictin, aurintricarboxylic acid, chloroamidine, ouabain, terazosin, prazosin, tranilast, apremilast, monobenzone, phenazopyridine, 546C88, NOX-100, gabexate mesilate, ulinastatin, somatostatin, octreotide, IKK inhibitor, caspase inhibitor, TAK-242, eritoran, ki16425, camptothecin, caffeic acid phenethyl ester, sulforaphane, Tim-3, BN-52021, BB-882, TCV- 309, CT-400, ethyl pyruvate, hemin, CORM-2, tanshinone IIA sulfonate, nicotine, EGCG, isorhamnetinO-galactoside, persicarin, catechin, carbenoxolone, glycyrrhizin, emodinO- b-D-glucoside, acteoside, forsythoside B, rosmarinic acid, chlorogenic acid, inflachromene, cilostazol, clopidogrel, sarpogrelate, drotrecogin alpha, carbamazepine, chloroquine, anakinra, tocilizumab, LMT-28, 1-(3-dimethylaminopropyl)ethylurea, gp130Fc, beta-arrestin 2, IL- , diacerein, secukinumab, ustekinumab, ixekizumab, thalidomide, adalimumab, infliximab, pravastatin, atorvastatin, rosuvastatin, simvastatin, losartan, telmisartan, hydrochlorothiazide, furosemide, propranolol, metoprolol, captopril, amlodipine, clonidine, methyldopa, minoxidil, streptozotocin, mitomycin, cisplatin, daunorubicin, doxorubicin, dactinomycin, bleomycin, mithramycin, anthramycin, calicheamicin, duocarmycin, vincristine, taxol, docetaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, , vinblastine, colchicine, dihydroxy anthracenedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, procaine, tetracaine, lidocaine, propranolol, tamoxifen, bazedoxifene, puromycin, anetholtrithion, nivolumab, pembrolizumab, ipilimumab, atezolizumab, alpha- galactosylceramide, SRT3025, DTA-1, IL-7, IL-2, IL-15, CXCL1, ATRA, gemcitabine, carboplatin, NCX-4016, CDDO-Me, sunitinib, zoledronic acid, Astragalus polysaccharide, rituximab, imuran, abatacept, GW9662, rosiglitazone, Y-27632, and alefacept, but is not limited thereto.
The composition may contain from 0.0001% by weight to 10% by weight, based on the total weight of the composition, of a 4-benzopyranone derivative, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof, preferably 0.001% by weight to 1% by weight, but not limited thereto.
In one embodiment of the present invention, the pharmaceutical composition for preventing or treating TNF-related diseases, containing the 4-benzopyranone derivative, pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient may be used in the form of any one of the formulations selected from the group consisting of injections, granules, powders, tablets, pills, capsules, suppositories, gels, suspensions, emulsions, drops, or solutions according to a customary method.
In another embodiment of the present invention, the pharmaceutical composition may further contain one or more additives selected from the group consisting of carriers, excipients, disintegrating agents, sweetening agents, coating agents, bulking agents, glidants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersing agents, surfactants, binders, and lubricants, which are appropriate to be customarily used in the preparation of the pharmaceutical composition.
Specifically, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil may be used as the carrier, excipient, and diluent. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin and the like into the composition. In addition to simple excipients, lubricants such as magnesium stearate, talc may be also used. Liquid preparations for oral administration include suspensions, solutions for internal use, emulsions, syrups and the like, and may comprise various excipients, for example wetting agents, sweetening agent, perfuming agents, preservatives and the like, in addition to water and liquid paraffin which are commonly used simple diluents. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories and the like. As non-aqueous solvents or suspending agents, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like may be used. As the base of the suppositories, witepsol, Macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used.
The preferred dosage of the 4-benzopyranone derivative, pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof may vary depending on the condition and body weight of the subject, the kind and severity of the disease, the form of the drug, administration route, and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the compound of the present invention may be administered in a daily dosage of 0.0001 to 100 mg/kg, preferably 0.001 to 100 mg/kg. The dose may be administered once per day or in several divided doses per day, and the scope of the present invention is not limited thereto.
In one embodiment of the present invention, the pharmaceutical composition may be administered to a mammal such as a rat, a mouse, a livestock, a human and the like in a variety of routes. All modes of administration may be expected, and the pharmaceutical composition may be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine, intrathecal, or intracerebroventricular injections.
In one embodiment of the present invention, the health functional food composition may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring agents and improving agents (cheese, chocolate and the like), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickening agents, pH adjusting agents, stabilizing agents, preservatives, glycerin, alcohols, carbonizing agents as used in carbonated beverages and the like. Additionally, the health functional food composition may contain fruit flesh for the preparation of natural fruit juices, synthetic fruit juices, and vegetable beverages. These components may be used independently or in combination. In addition, the health functional food composition may be in the form of any one of meats, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, gum, ice cream, soups, beverages, teas, functional water, drinks, alcoholic beverages, and multi-vitamin preparations.
In addition, the health functional food composition may further comprise a food additive, and the suitability of the additive as a "food additive" is determined based on a standard and criteria relating to the concerned item according to general rules and general test methods and the like of the Korean Food Additives Code that has been approved by the Ministry of Food and Drug Safety as long as other rules are not provided.
The items disclosed in the "Korean Food Additives Code" include, for example, a chemically synthetic product, such as ketone, glycine, calcium citrate, nicotinic acid, cinnamic acid and the like, a natural additive product, such as persimmon color, a licorice extract, microcrystalline cellulose, Kaoliang color, guar gum and the like, and mixed preparations, such as a sodium L-glutamate preparation, an alkali agent for noodles, a preservative preparation, a tar color preparation and the like.
In this regard, the content of the 4-benzopyranone derivative, pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof which is added to foods during the preparation of the health functional food composition may be appropriately increased or decreased, if necessary, and may be added to be included preferably in an amount of 1% by weight to 90% by weight.
Furthermore, the present invention provides a method for treating TNF-related diseases, comprising a step of treating with a 4-benzopyranone derivative represented by Formula 1, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof in a pharmaceutically effective amount: in which, R is heteroaryl or substituted phenyl; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
Specifically, in Formula 1 above, R may be furanyl, thiophenyl, or substituted phenyl 3 4 5 6 7 8 9 10 11 represented by , and R , R , R , R , R , R , R , R , and R may be each independently hydrogen, chloro, bromo, fluoro, or methoxy.
More specifically, the 4-benzopyranone derivative may be selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethyl-(4H)benzopyranone; 2-(2-furanyl)carboxymethyl- (4H)benzopyranone; 2-(2-furanyl)carboxymethyl-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(3- methylphenyl)carboxy-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2- (3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-methylphenyl) carboxymethyl-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H)benzopyranone; 2-(3- methylphenyl)carboxychloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxy chloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxybromo-(4H) benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxy chloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H) benzopyranone; 2-(3-fluorophenyl)carboxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3- fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy chloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxybromo-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy methyl-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4- chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
In this regard, the TNF-related disease may be any one selected from the group consisting of autoimmune diseases, inflammatory diseases, cardiovascular diseases, metabolic diseases, immune disorders, neurological diseases, ophthalmic diseases, skin diseases, psychiatric diseases, infectious diseases, and cancers, but is not limited thereto.
Specifically, the TNF-related disease may be any one selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, polymyalgia rheumatica, multiple sclerosis, thyroiditis, delayed hypersensitivity, allergy, contact dermatitis, atopic dermatitis, systemic lupus erythematosus, systemic sclerosis, adult-onset Still's disease, asthma, autoimmune thyroid disorder, Sjogren's syndrome, Kawasaki disease, pancreatitis, nephritis, hepatitis, pneumonia, chronic obstructive pulmonary disease, otitis media, angioplasia nephritis, myelodysplastic syndrome, osteoarthritis, sarcoidosis, granuloma annulare, Wegener's granulomatosis, lupus, hemolytic uremic syndrome, arteriosclerosis, vasculitis, heart failure, stroke, myocardial infarction, myocardial ischemia-reperfusion injury, sexual dysfunction, obesity, hypertension, diabetes mellitus and diabetic complication, hyperlipidemia, preeclampsia, kidney disease, liver disease, kidney injury, liver injury, snake bite, allograft rejection, organ transplantation, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, pain, central nervous system disease, uveitis, Behcet's disease, diabetic macular edema, macular degeneration, orbitopathy, glaucoma, hidradenitis suppurativa, multicentric reticulohistiocytosis, pityriasis rubra pilaris, eosinophilic fascilitis, panniculitis, necrobiosis lipoidica diabeticorum, cicatricial pemphigoid, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, toxic epidermal necrolysis, pustular dermatitis, dermatomyositis, polymyositis, bullous dermatosis, erythema nodosum, alopecia, depressive disorder, bipolar disorder, anxiety disorder, tuberculosis, viral infection, bacterial infection, fungal infection, protozoan infection, cerebral malaria, sepsis, septic shock, prostate cancer, skin cancer, colorectal cancer, kidney cancer, pancreatic cancer, ovarian cancer, breast cancer, bladder cancer, prostate cancer, lymphoma, glioma, osteosarcoma, leukemia, multiple myeloma, and cachexia, but is not limited thereto.
As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient for a drug to be administered to an animal or a human to exhibit the desired physiological or pharmacological activity. However, the pharmaceutically effective amount may be appropriately changed depending on the age, body weight, health condition, and sex of the subject to be administered, administration routes, and the duration of treatment and the like.
In addition, as used herein, the term "pharmaceutically acceptable" refers to being physiologically acceptable and does not customarily cause an allergic reaction such as gastrointestinal disorder, dizziness and the like or a reaction similar thereto when administered to a human. Examples of the carrier, excipient, and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, it may further comprise a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and a preservative and the like.
In addition, the present invention provides a reagent composition for inhibiting a TNF activity in vitro, containing a 4-benzopyranone derivative represented by Formula 1, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof as an active ingredient: in which, R is heteroaryl or substituted phenyl; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
Furthermore, the present invention provides a method for inhibiting a TNF activity, comprising a step of treating an animal excluding a human with a 4-benzopyranone derivative represented by Formula 1 above, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof.
Specifically, in Formula 1 above, R may be furanyl, thiophenyl, or substituted phenyl 3 4 5 6 7 8 9 10 11 represented by , and R , R , R , R , R , R , R , R , and R may be each independently hydrogen, chloro, bromo, fluoro, or methoxy.
More specifically, the 4-benzopyranone derivative may be selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethyl-(4H)benzopyranone; 2-(2-furanyl)carboxymethyl- (4H)benzopyranone; 2-(2-furanyl)carboxymethyl-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(3- methylphenyl)carboxy-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2- (3-methylphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-methylphenyl) carboxymethyl-(4H)benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone; 2-(3-methylphenyl)carboxymethyl-(4H)benzopyranone; 2-(3- methylphenyl)carboxychloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxy chloro-(4H)benzopyranone; 2-(3-methylphenyl)carboxybromo-(4H) benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethyl-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxy chloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxychloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy- (4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H) benzopyranone; 2-(3-fluorophenyl)carboxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3- fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy chloro-(4H)benzopyranone; 2-(3-fluorophenyl)carboxybromo-(4H) benzopyranone; 2-(3-fluorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy methyl-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone; 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,3-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxymethyl-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)- 4-benzopyranone; 2-(3,4-difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone; 2-(3,4-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone; 2-(4-chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4- chlorophenyl)carboxymethyl-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
Embodiment for Working the Invention Hereinafter, the present invention will be described in more detail through the working examples in order to promote understanding of the present invention. However, the following examples are provided for a better understanding of the present invention to one of ordinary skill in the art, and are only illustrations of the present invention, but the scope of the present invention is not limited to the following examples.
General reaction process of 4-benzopyranone compound derivative [Reaction Scheme 1] First, a 2-hydroxybenzophosphorane derivative compound (2) was dissolved in carbon dichloride, and pyridine (2 eq) was added dropwise thereto. Then, a heteroaromatic or benzoyl chloride derivative (1.5 eq) was added dropwise, and 4-dimethylaminopyridine (0.05 eq) was added dropwise thereto. Then, the reaction was stirred under a nitrogen atmosphere for 1 hour to 5 hours. When the reaction was completed, acetic acid (1 mL) was added to the reaction solution, and Girard's reagent T (1 eq) was added dropwise, and then the mixture was stirred under a nitrogen atmosphere for 1 hour. The mixture was extracted with 1N HCl and saturated NaHCO solution. The organic layer was dried over anhydrous MgSO , and then filtered and distilled under reduced pressure to obtain the compound (3). The compound (3) was dissolved in a solvent toluene. After refluxing with heating under a nitrogen atmosphere for 5 to 18 hours, when the reaction was completed, the solvent was removed by distillation under reduced pressure, and then the reaction was purified by chromatography. The thus obtained 4- benzopyranone compound (4) was dissolved in carbon dichloride, and TFA was added dropwise, and the mixture was stirred under a nitrogen atmosphere for 1 hour to 5 hours. When the reaction was completed, the solvent was removed by distillation under reduced pressure.
The crystals obtained by crystallization with ether were filtered and then dried in a vacuum oven to obtain the final desired compounds (5).
Synthesis of 2-(3-fluorophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (150 mg, 0.28 mmol), pyridine (0.05 mL, 0.57 mmol, 2 eq), and 3-fluorobenzoyl chloride (0.05 mL, 0.43 mmol, 1.5 eq) were stirred in carbon dichloride (5 mL) for 4 hours and 30 minutes, and stirred in toluene (10 mL) for 2 hours and minutes, and then stirred in TFA (2 mL) and carbon dichloride (2 mL) for 1 hour and 30 minutes to obtain 60 mg (67.0%) of the final desired compound, 2-(3-fluorophenyl)carboxy- 7-methoxy-(4H)benzopyranone. m.p. 214-215 ºC. H NMR (300 MHz, CDCl ): d 3.96 (s, 3H), 6.97 (d, J = 2.3 Hz, 1H), 7.15 (dd, J= 9.1, 2.3 Hz, 1H), 7.26-7.50 (m, 4H), 8.24 (d, J= 9.1 Hz, 1H); C NMR (75 MHz, CDCl ): d 56.22, 100.21, 110.10, 115.48, 116.14, 116.91, 118.53, 124.96, 127.77, 129.86, 134.56, 157.54, 160.45, 163.56, 166.12, 172.04, 179.62.
Synthesis of 2-(2-furanyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methoxybenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-furoyl chloride (0.029 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 25.2 mg (47.6%) of the final desired compound, 2-(2-furanyl) carboxymethoxy-(4H)benzopyranone. m.p. 195-197 ºC. H NMR (300 MHz, CDCl ): d 2.53 (s, 3H), 6.71 (dd, J = 3.7, 1.7 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.6, 2.0 Hz, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 3.7 Hz, 1H), 8.09 (s, 1H), 14.55 (s, 1H).
Synthesis of 2-(2-furanyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.06 mL, 0.76 mmol, 2 eq), and 2-furoyl chloride (0.05 mL, 0.57 mmol, 1.5 eq) were stirred in carbon dichloride (4 mL) for 1 hour, and stirred in toluene (15 mL) for 10 hours, and then stirred in TFA (2 mL) and carbon dichloride (2 mL) for 4 hours to obtain 50 mg (46.0%) of the final desired compound, 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone. m.p. 217-219 ºC. H NMR (300 MHz, CDCl ): d 3.99 (s, 3H), 6.71 (dd, J = 3.7, 1.6 Hz, 1H), 7.03 (d, J = 2.3 Hz, 1H), 7.11 (dd, J = 9.0, 2.3 Hz, 1H), 7.78 (d, J = 1.6 Hz, 1H), 8.01 (d, J = 3.7 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 15.00 (s, 1H).
Synthesis of 2-(2-furanyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.06 mL, 0.76 mmol, 2 eq), and 2-furoyl chloride (0.05 mL, 0.57 mmol, 1.5 eq) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (15 mL) for 10 hours, and then stirred in TFA (2 mL) and methylene chloride (2 mL) for 4 hours to obtain 70 mg (64.0%) of the final desired compound, 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone. m.p. 205-207 ºC. H NMR (300 MHz, CDCl ): d 3.97 (s, 3H), 6.71 (dd, J = 3.7, 1.7 Hz, 1H), 7.43 (dd, J = 9.2, 3.1 Hz, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.64 (d, J = 3.1 Hz, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 3.7 Hz, 1H), 14.60 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methoxybenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), m-toluoyl chloride (0.031 mL, 0.24 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 14 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 23.1 mg (40.1%) of the final desired compound, 2- (3-methylphenyl)carboxymethoxy-(4H)benzopyranone. m.p. 192-195 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 2.55 (s, 3H), 7.41-7.47 (m, 4H), 7.52 (d, J= 8.6 Hz, 1H), 7.67 (dd, J= 8.6, 2.1 Hz, 1H), 8.14 (d, J= 0.9 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.06 mL, 0.76 mmol, 2 eq), and m-toluoyl chloride (0.05 mL, 0.57 mmol, 1.5 eq) were stirred in methylene chloride (4 mL) for 19 hours, and stirred in toluene (15 mL) for 17 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 76.3 mg (65.0%) of the final desired compound, 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone. m.p. 183-184 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 3.96 (s, 3H), 6.98 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 9.0, 2.3 Hz, 1H), 7.40-7.46 (m, 4H), 8.25 (d, J = 9.0 Hz, 1H), 14.45 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.06 mL, 0.76 mmol, 2 eq), and m-toluoyl chloride (0.05 mL, 0.57 mmol, 1.5 eq) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (15 mL) for 71 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 49.5 mg (42.0%) of the final desired compound, 2-(3-methylphenyl)carboxymethoxy-(4H)benzopyranone. m.p. 198-199 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 3.98 (s, 3H), 7.27-7.46 (m, 5H), 7.56 (d, J = 9.2 Hz, 1H), 7.67 (d, J = 3.0 Hz, 1H), 14.35 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (200 mg, 0.4 mmol), pyridine (0.05 mL, 0.6 mmol, 1.5 eq), and 3,4-dimethoxybenzoyl chloride (96 mg, 0.48 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 150 hours, and stirred in toluene (15 mL) for 72 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 34.9 mg (63.0%) of the final desired compound, 2-(3,4-dimethoxyphenyl)carboxy-(4H)benzopyranone. m.p. 237-238 ºC. H NMR (300 MHz, CDCl ): d 3.94 (s, 3H), 3.99 (s, 3H), 7.00 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 2.1 Hz, 1H), 7.39 (dd, J = 8.4, 2.1 Hz, 1H), 7.56-7.64 (m, 2H), 7.64- 7.90 (m, 1H), 8.36 (dd, J = 8.0, 1.6 Hz, 1H), 14.50 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H)- 4-benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.05 mL, 0.57 mmol, 1.5 eq), and 3,4-dimethoxybenzoyl chloride (92 mg, 0.46 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 12 hours, and stirred in benzene (10 mL) for 45 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 59.7 mg (89.0%) of the final desired compound, 2-(3,4-dimethoxyphenyl)carboxymethoxy-(4H) benzopyranone.
H NMR (300 MHz, CDCl ): d 3.94 (s, 3H), 3.96 (s, 3H), 3.97 (s, m.p. 208-210 ºC. 3 3H), 6.97-6.99 (m, 2H), 7.12 (dd, J = 8.9, 2.3 Hz, 1H), 7.20 (d, J = 1.9 Hz, 1H), 7.34 (dd, J = 8.4, 1.9 Hz, 1H), 8.22 (d, J = 8.9 Hz, 1H).
Synthesis of 2-(2-chlorophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.05 mL, 0.57 mmol, 1.5 eq), and 2-chlorobenzoyl chloride (0.06 mL, 0.46 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (15 mL) for 8 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 70 mg (88.0%) of the desired compound, 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone. m.p. 130-132 ºC. H NMR (300 MHz, CDCl ): d 3.96 (s, 3H), 6.98 (d, J = 2.4 Hz, 1H), 7.17 (dd, J = 9.0, 2.4 Hz, 1H), 7.43-7.44 (m, 2H), 7.48-7.56 (m, 2H), 8.28 (d, J = 9.0 Hz, 1H), 14.40 (s, 1H).
Synthesis of 2-(2-chlorophenyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (200 mg, 0.40 mmol), pyridine (0.05 mL, 0.60 mmol, 1.5 eq), and 2-chlorobenzoyl chloride (0.06 mL, 0.48 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (15 mL) for 120 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 6 hours and 30 minutes to obtain 34 mg (44.0%) of the final desired compound, 2-(2-chlorophenyl)carboxy-(4H)benzopyranone. m.p. 133-135 ºC. H NMR (300 MHz, CDCl ): d 7.44-7.46 (m, 2H), 7.49-7.55 (m, 2H), 7.61-7.66 (m, 2H), 7.87-7.93 (m, 1H), 8.40 (dd, J = 8.3, 1.7 Hz, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.05 mL, 0.57 mmol, 1.5 eq), and 2-thiophenecarbonyl chloride (0.05 mL, 0.46 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 2 hours and 30 minutes, and stirred in toluene (15 mL) for 36 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 52.4 mg (56.0%) of the final desired compound, 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone. m.p. 196-198 ºC. H NMR (300 MHz, CDCl ): d 4.07 (s, 3H), 7.25 (dd, J = 5.0, 4.0 Hz, 1H), 7.31 (dd, J = 8.1, 1.3 Hz, 1H), 7.46 (dd, J = 8.1, 8.1 Hz, 1H), 7.81-7.85 (m, 2H), 8.38 (dd, J = 4.0, 1.2 Hz, 1H), 14.80 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.05 mL, 0.57 mmol, 1.5 eq), and 2-thiophenecarbonyl chloride (0.05 mL, 0.46 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 2 hours and 30 minutes, and stirred in toluene (15 mL) for 28 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 41 mg (77.0%) of the final desired compound, 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone. m.p. 205-207 ºC. H NMR (300 MHz, CDCl ): d 3.97 (s, 3H), 6.95 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 9.0, 2.3 Hz, 1H), 7.22 (dd, J = 5.0, 4.0 Hz, 1H), 7.79 (dd, J = 5.0, 1.1 Hz, 1H), 8.19 (d, J = 9.0 Hz, 1H), 8.25 (dd, J = 4.0, 1.1 Hz, 1H), 14.98 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methoxybenzophosphorane compound (200 mg, 0.38 mmol), pyridine (0.05 mL, 0.57 mmol, 1.5 eq), and 2-thiophenecarbonyl chloride (0.05 mL, 0.46 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 2 hours and 30 minutes, and stirred in toluene (15 mL) for 42 hours, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 1 hour and 30 minutes to obtain 50 mg (68.0%) of the final desired compound, 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone. m.p. 172-174 ºC. H NMR (300 MHz, CDCl ): d 3.96 (s, 3H), 7.24 (dd, J = 5.0, 4.0 Hz, 1H), 7.43 (dd, J = 9.2, 3.0 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.63 (d, J = 3.0 Hz, 1H), 7.81 (dd, J = 5.0, 1.2 Hz, 1H), 8.25 (dd, J = 4.0, 1.2 Hz, 1H), 14.78 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (200 mg, 0.40 mmol), pyridine (0.05 mL, 0.60 mmol, 1.5 eq), and 2-thiophenecarbonyl chloride (0.05 mL, 0.48 mmol, 1.2 eq) were stirred in methylene chloride (4 mL) for 3 hours, and stirred in toluene (15 mL) for 23 hours and 30 minutes, and then stirred in TFA (5 mL) and methylene chloride (5 mL) for 2 hours to obtain 52.3 mg (78.0%) of the final desired compound, 2-(2-thiophenyl)carboxy-(4H) benzopyranone. m.p. 175-176 ºC. H NMR (300 MHz, CDCl ): d 7.25 (dd, J= 5.0, 4.1 Hz, 1H), 7.55- 7.64 (m, 2H), 7.83-7.89 (m, 2H), 8.29-8.34 (m, 2H), 14.70 (s, 1H).
Synthesis of 2-(3-fluorophenyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (300 mg, 0.6 mmol), diisopropylethylamine (0.314 mL, 1.8 mmol, 3 eq), 3-fluorobenzoyl chloride (0.118 mL, 1.2 mmol, 2 eq), and 4- (dimethylamino)pyridine (10 mg) were stirred in methylene chloride (5 mL) for 1 hour, and stirred in toluene (15 mL) for 4 hours and 30 minutes, and then stirred in TFA (7 mL) and methylene chloride (7 mL) for 1 hour and 30 minutes to obtain 154 mg (90.0%) of the final desired compound, 2-(3-fluorophenyl)carboxy-(4H)benzopyranone. m.p. 193-196 ºC. H NMR (300 MHz, CDCl ): d 7.29-7.55 (m, 4H), 7.60-7.65 (m, 2H), 7.87-7.93 (m, 1H), 8.37-8.40 (m, 1H), 14.19 (s, 1H).
Synthesis of 2-(3,5-difluorophenyl)carboxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (300 mg, 0.6 mmol), diisopropylethylamine (0.314 mL, 1.8 mmol, 3 eq), 3,5-difluorobenzoyl chloride (0.15 mL, 1.2 mmol, 2 eq), and 4- (dimethylamino)pyridine (10 mg) were stirred in methylene chloride (5 mL) for 1 hour, and stirred in toluene (15 mL) for 2 hours and 30 minutes, and then stirred in TFA (7 mL) and methylene chloride (7 mL) for 1 hour to obtain 22 mg (12.0%) of the final desired compound, 2-(3,5-difluorophenyl)carboxy-(4H)benzopyranone. m.p. 208-209 ºC. H NMR (300 MHz, CDCl ): d 7.02-7.08 (m, 1H), 7.16-7.19 (m, 2H), 7.62-66 (m, 2H), 7.89-7.94 (m, 1H), 8.38 (d, J = 8.3 Hz, 1H).
Synthesis of 2-(2-furanyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (300 mg, 0.6 mmol), diisopropylethylamine (0.314 mL, 1.8 mmol, 3 eq), 2-furoyl chloride (0.118 mL, 1.2 mmol, 2 eq), and 4-(dimethylamino)pyridine (10 mg) were stirred in methylene chloride (5 mL) for 1 hour, and stirred in toluene (15 mL) for 8 hours, and then stirred in TFA (7 mL) and methylene chloride (7 mL) for 1 hour to obtain 96 mg (62.0%) of the final desired compound, 2-(2-furanyl)carboxy-(4H)benzopyranone. m.p. 202-205 ºC. H NMR (300 MHz, CDCl ): d 6.72 (dd, J = 3.8, 1.7 Hz, 1H), 7.54- 7.60 (m, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.81-7.89 (m, 2H), 8.01-8.03 (m, 1H), 8.32 (dd, J = 8.0, 1.5 Hz, 1H), 14.45 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (300 mg, 0.6 mmol), diisopropylethylamine (0.314 mL, 1.8 mmol, 3 eq), m-toluoyl chloride (0.158 mL, 1.2 mmol, 2 eq), and 4- (dimethylamino)pyridine (10 mg) were stirred in methylene chloride (5 mL) for 1 hour, and stirred in toluene (15 mL) for 72 hours, and then stirred in TFA (7 mL) and methylene chloride (7 mL) for 1 hour to obtain 73 mg (43.0%) of the final desired compound, 2-(3-methylphenyl)- 3-carboxy-(4H)benzopyranone. m.p. 162-164 ºC. H NMR (300 MHz, CDCl ): d 2.48 (s, 3H), 7.43-7.50 (m, 4H), 7.59- 7.65 (m, 2H), 7.86-7.92 (m, 1H), 8.38 (dd, J = 8.0, 1.5 Hz, 1H), 14.20 (s, 1H).
Synthesis of 2-(2-furanyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-furoyl chloride (0.029 mL, 0.30 mmol, 1.5 eq), 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 31.4 mg (59.3%) of the final desired compound, 2-(2-furanyl) carboxymethyl-(4H)benzopyranone. m.p. 227-228 ºC. H NMR (300 MHz, CDCl ): d 2.58 (s, 3H), 6.69 (dd, J = 3.6, 1.7 Hz, 1H), 7.32-7.36 (m, 2H), 7.59 (d, J = 7.3 Hz, 1H), 7.76-7.77 (m, 1H), 7.98 (d, J = 7.3 Hz, Synthesis of 2-(2-furanyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-furoyl chloride (0.029 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 19.1 mg (36.1%) of the final desired compound, 2-(2-furanyl) carboxymethyl-(4H)benzopyranone. m.p. 217-218 ºC. H NMR (300 MHz, CDCl ): d 2.57 (s, 3H), 6.71 (dd, J = 3.7, 1.7 Hz, 1H), 7.37 (dd, J = 8.2, 0.8 Hz, 1H), 7.46 (s, 1H), 7.79 (d, J = 1.7 Hz, 1H), 8.00 (d, J = 3.7 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 14.55 (s, 1H).
Synthesis of 2-(2-furanyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-furoyl chloride (0.029 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 25.2 mg (47.6%) of the final desired compound, 2-(2-furanyl) carboxymethyl-(4H)benzopyranone. m.p. 195-197 ºC. H NMR (300 MHz, CDCl ): d 2.53 (s, 3H), 6.71 (dd, J = 3.7, 1.7 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.6, 2.0 Hz, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 3.7 Hz, 1H), 8.09 (s, 1H), 14.55 (s, 1H).
Synthesis of 2-(2-furanyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 2-furoyl chloride (0.028 mL, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 20.20 mg (36.9%) of the final desired compound, 2-(2-furanyl) carboxychloro-(4H)benzopyranone. m.p. 196-198 ºC. H NMR (300 MHz, CDCl ): d 6.73 (dd, J = 3.8, 1.7 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.77-7.81 (m, 2H), 8.04 (dd, J = 3.8, 0.5 Hz, 1H), 8.27 (d, J = 2.5 Hz, 1H), 14.00 (s, 1H).
Synthesis of 2-(2-furanyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (100 mg, 0.17 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol, 2 eq), 2-furoyl chloride (0.026 mL, 0.26 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 50 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 41.9 mg (71.9%) of the final desired compound, 2-(2-furanyl) carboxybromo-(4H)benzopyranone. m.p. 209-211 ºC. H NMR (300 MHz, CDCl3): d 6.73 (dd, J = 3.8, 1.6 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 7.80-7.81 (m, 1H), 7.93 (dd, J = 8.9, 2.4 Hz, 1H), 8.03 (d, J = 3.8 Hz, 1H), 8.43 (d, J = 2.4 Hz, 1H), 14.25 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), m-toluoyl chloride (0.031 mL, 0.24 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 14.0 mg (24.3%) of the final desired compound, 2- (3-methylphenyl)carboxymethyl-(4H)benzopyranone. m.p. 209-211 ºC. H NMR (300 MHz, CDCl ): d 2.47 (s, 3H), 2.55 (s, 3H), 7.42-7.51 (m, 5H), 7.70 (d, J = 7.1 Hz, 1H), 8.19 (d, J = 7.1 Hz, 1H), 14.25 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), m-toluoyl chloride (0.031 mL, 0.24 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 23.2 mg (40.4%) of the final desired compound, 2- (3-methylphenyl)carboxymethyl-(4H)benzopyranone. m.p. 152-155 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 2.57 (s, 3H), 7.39-7.47 (m, 6H), 8.24 (d, J = 8.5 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), m-toluoyl chloride (0.031 mL, 0.24 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 23.1 mg (40.1%) of the final desired compound, 2- (3-methylphenyl)carboxymethyl-(4H)benzopyranone. m.p. 192-195 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 2.55 (s, 3H), 7.41-7.47 (m, 4H), 7.52 (d, J = 8.6 Hz, 1H), 7.67 (dd, J = 8.6, 2.1 Hz, 1H), 8.14 (d, J = 0.9 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), m-toluoyl chloride (0.030 mL, 0.23 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 28.4 mg (48.0%) of the final desired compound, 2- (3-methylphenyl)carboxychloro-(4H)benzopyranone. m.p. 179-181 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 7.43-7.46 (m, 4H), 7.56 (dd, J = 8.6, 1.5 Hz, 1H), 7.66 (s, 1H), 8.30 (d, J = 8.6 Hz, 1H), 13.95 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), m-toluoyl chloride (0.030 mL, 0.23 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 13.4 mg (22.6%) of the final desired compound, 2- (3-methylphenyl)carboxychloro-(4H)benzopyranone. m.p. 218-220 ºC. H NMR (300 MHz, CDCl ): d 2.46 (s, 3H), 7.44-7.47 (m, 4H), 7.52 (d, J = 8.9 Hz, 1H), 7.95 (dd, J = 8.9, 2.4 Hz, 1H), 8.49 (d, J = 2.4 Hz, 1H), 13.80 (s, 1H).
Synthesis of 2-(3-methylphenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (100 mg, 0.17 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol, 2 eq), m-toluoyl chloride (0.027 mL, 0.20 mmol, 1.2 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 144 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour and 30 minutes to obtain 21.6 mg (34.6%) of the final desired compound, 2- (3-methylphenyl)carboxybromo-(4H)benzopyranone. m.p. 208-210 ºC. H NMR (300 MHz, CDCl ): d 2.47 (s, 3H), 7.42-7.47 (m, 4H), 7.59 (d, J = 8.9 Hz, 1H), 7.80 (dd, J = 8.9, 2.5 Hz, 1H), 8.32 (d, J = 2.5 Hz, 1H), 13.90 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.031 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 21 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 26.5 mg (47.3%) of the final desired compound, 2-(2-thiophenyl)- 3-carboxymethyl-(4H)benzopyranone. m.p. 205-206 ºC. H NMR (300 MHz, CDCl ): d 2.63 (s, 3H), 7.25-7.26 (m, 4H), 7.45 (dd, J = 7.7, 7.7 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.83 (dd, J = 5.0, 1.0 Hz, 1H), 8.14 (d, J = 7.7 Hz, 1H), 8.38 (dd, J = 4.0, 1.0 Hz, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.031 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 21 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 30.1 mg (53.8%) of the final desired compound, 2-(2-thiophenyl)- 3-carboxymethyl-(4H)benzopyranone. m.p. 202-203 ºC. H NMR (300 MHz, CDCl ): d 2.58 (s, 3H), 7.24 (dd, J = 5.0, 4.0 Hz, 1H), 7.37 (d, J = 8.2 Hz, 1H), 7.42 (s, 1H), 7.82 (dd, J = 5.0, 1.1 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 8.28 (dd, J = 4.0, 1.1 Hz, 1H), 14.80 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.031 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 30 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 50 mg (89%) of the final desired compound, 2-(2-thiophenyl) carboxymethyl-(4H)benzopyranone. m.p. 153-155 ºC. H NMR (300 MHz, CDCl ): d 2.54 (s, 3H), 7.24 (dd, J = 5.0, 4.0 Hz, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.6, 2.0 Hz, 1H), 7.82 (dd, J = 5.0, 1.1 Hz, 1H), 8.09 (s, 1H), 8.28 (dd, J = 4.0, 1.1 Hz, 1H), 14.75 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.030 mL, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 24 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 37.0 mg (63.8%) of the final desired compound, 2-(2-thiophenyl)- 3-carboxychloro-(4H)benzopyranone. m.p. 232-233 ºC. H NMR (300 MHz, CDCl ): d 7.20 (dd, J = 5.0, 4.0 Hz, 1H), 7.42 (dd, J = 8.5, 1.8 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.73 (dd, J = 5.0, 1.0 Hz, 1H), 7.93 (dd, J = 4.0, 1.0 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H).
Synthesis of 2-(2-thiophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.030 mL, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 72 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 36.7 mg (63.3%) of the final desired compound, 2-(2-thiophenyl)- 3-carboxychloro-(4H)benzopyranone.
H NMR (300 MHz, CDCl ): d 7.24 (dd, J = 5.0, 4.0 Hz, 1H), 7.57 m.p. 202-204 ºC. 3 (d, J = 8.9 Hz, 1H), 7.77 (dd, J = 8.9, 2.5 Hz, 1H), 7.84 (dd, J = 5.0, 1.1 Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 8.28 (dd, J = 4.0, 1.1 Hz, 1H), 14.45 (s, 1H).
Synthesis of 2-(2-thiophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (100 mg, 0.17 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.028 mL, 0.26 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 72 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 46.2 mg (75.7%) of the final desired compound, 2-(2-thiophenyl)- 3-carboxybromo-(4H)benzopyranone. m.p. 210-212 ºC. H NMR (300 MHz, CDCl ): d 7.25 (dd, J = 5.0, 4.1 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.86 (dd, J = 5.0, 1.1 Hz, 1H), 7.93 (dd, J = 8.9, 2.4 Hz, 1H), 8.30 (dd, J = 4.1, 1.1 Hz, 1H), 8.44 (d, J = 2.4 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 3,4-dimethoxybenzoyl chloride (59 mg, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 96 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 20.3 mg (30.3%) of the final desired compound, 2-(3,4- dimethoxyphenyl)carboxymethyl-(4H)benzopyranone. m.p. 210-212 ºC. H NMR (300 MHz, CDCl ): d 2.58 (s, 3H), 3.96 (s, 3H), 4.00 (s, 3H), 7.01 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 2.1 Hz, 1H), 7.43 (dd, J = 8.5, 2.1 Hz, 1H), 7.48 (dd, J = 7.7, 7.7 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 8.18 (d, J = 7.7 Hz, 1H), 14.45 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 3,4-dimethoxybenzoyl chloride (59 mg, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 24 hours, and stirred in toluene (6 mL) for 96 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 28.4 mg (42.4%) of the final desired compound, 2-(3,4- dimethoxyphenyl)carboxymethyl-(4H)benzopyranone. m.p. 200-201 ºC. H NMR (300 MHz, CDCl ): d 2.58 (s, 3H), 3.96 (s, 3H), 3.99 (s, 3H), 6.99 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 7.36-7.43 (m, 3H), 8.22 (d, J = 8.1 Hz, 1H), 14.45 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 3,4-dimethoxybenzoyl chloride (57 mg, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 100 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 34.8 mg (51.2%) of the final desired compound, 2-(3,4- dimethoxyphenyl)carboxychloro-(4H)benzopyranone. m.p. 226-227 ºC. H NMR (300 MHz, CDCl ): d 3.95 (s, 3H), 3.99 (s, 3H), 6.99 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 2.1 Hz, 1H), 7.38 (dd, J = 8.4, 2.1 Hz, 1H), 7.54 (dd, J = 8.6, 1.8 Hz, 1H), 7.66 (dd, J = 1.8 Hz, 1H), 8.28 (d, J = 8.6 Hz, 1H), 14.10 (s, 1H).
Synthesis of 2-(3,4-dimethoxyphenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (100 mg, 0.17 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol, 2 eq), 2-thiophenecarbonyl chloride (0.028 mL, 0.26 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 92 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 34 mg (48%) of the final desired compound, 2-(3,4- dimethoxyphenyl)carboxybromo-(4H)benzopyranone. m.p. 242-243 ºC. H NMR (300 MHz, CDCl ): d 3.95 (s, 3H), 3.99 (s, 3H), 6.99 (d, J = 8.4 Hz, 1H), 7.22 (d, J = 2.1 Hz, 1H), 7.38 (dd, J = 8.4, 2.1 Hz, 1H), 7.53 (d, J = 8.9 Hz, 1H), 7.94 (dd, J = 8.9, 2.4 Hz, 1H), 8.48 (d, J = 2.4 Hz, 1H).
Synthesis of 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 3-fluorobenzoyl chloride (0.036 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 12 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 2 hours to obtain 18.7 mg (32.2%) of the final desired compound, 2-(3- fluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 227-229 ºC. H NMR (300 MHz, CDCl ): d 2.54 (s, 3H), 7.28-7.33 (m, 1H), 7.39 (d, J = 9.3 Hz, 1H), 7.46-7.49 (m. 3H), 7.71 (d, J = 7.5 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H).
Synthesis of 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 3-fluorobenzoyl chloride (0.036 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 10 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 2 hours to obtain 16.1 mg (27.8%) of the final desired compound, 2-(3- fluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 178-181 ºC. H NMR (300 MHz, CDCl3): d 2.58 (s, 3H), 7.28-7.38 (m, 2H), 7.42- 7.44 (m, 3H), 7.47-7.54 (m. 1H), 8.23-8.26 (m, 1H), 14.33 (s, 1H).
Synthesis of 2-(3-fluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (100 mg, 0.20 mmol), diisopropylethylamine (0.068 mL, 0.40 mmol, 2 eq), 3-fluorobenzoyl chloride (0.036 mL, 0.30 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 21 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 2 hours to obtain 34.2 mg (59.0%) of the final desired compound, 2-(3- fluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 214-215 ºC. H NMR (300 MHz, CDCl ): d 2.56 (s, 3H), 7.30-7.33 (m, 1H), 7.35- 7.39 (m, 1H), 7.42-7.45 (m, 1H), 7.47-7.54 (m. 2H), 7.69 (dd, J = 8.6, 2.0 Hz, 1H), 8.14 (s, 1H), 14.30 (s, 1H).
Synthesis of 2-(3-fluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 3-fluorobenzoyl chloride (0.034 mL, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 19 hours , and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 2 hours to obtain 43 mg (71.6%) of the final desired compound, 2-(3-fluorophenyl)- 3-carboxychloro-(4H)benzopyranone. m.p. 160-163 ºC. H NMR (300 MHz, CDCl ): d 7.30-7.44 (m, 2H), 7.51 (dd, J = 8.0, .4 Hz, 1H), 7.58 (dd, J = 8.6, 1.8 Hz, 1H), 7.66 (d, J = 1.8 Hz, 1H), 7.71-7.75 (m, 1H), 8.31 (d, J = 8.6 Hz, 1H), 15.35 (s, 1H).
Synthesis of 2-(3-fluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (100 mg, 0.19 mmol), diisopropylethylamine (0.066 mL, 0.38 mmol, 2 eq), 3-fluorobenzoyl chloride (0.034 mL, 0.29 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 2 hours, and stirred in toluene (6 mL) for 24 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 2 hours to obtain 48.0 mg (80.0%) of the final desired compound, 2-(3- fluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 216-217 ºC. H NMR (300 MHz, CDCl3): d 7.29-7.39 (m, 2H), 7.42-7.46 (m, 1H), 7.49-7.56 (m, 1H), 7.60 (d, J = 8.9 Hz, 1H), 7.83 (dd, J = 8.9, 2.5 Hz, 1H), 8.33 (d, J = 2.5 Hz, 1H), 13.80 (s, 1H).
Synthesis of 2-(3-fluorophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (100 mg, 0.17 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol, 2 eq), 3-fluorobenzoyl chloride (0.032 mL, 0.26 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (3 mL) for 1 hour, and stirred in toluene (6 mL) for 24 hours, and then stirred in TFA (3 mL) and methylene chloride (3 mL) for 1 hour to obtain 44.9 mg (71.3%) of the final desired compound, 2-(3-fluorophenyl)- 3-carboxybromo-(4H)benzopyranone. m.p. 222-223 ºC. H NMR (300 MHz, CDCl ): d 7.32-7.38 (m, 2H), 7.44 (d, J = 7.8 Hz, 1H), 7.48-7.55 (m. 2H), 7.97 (dd, J = 9.7, 2.3 Hz, 1H), 8.50 (d, J = 2.3 Hz, 1H), 13.85 (s, Synthesis of 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 7 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 92.2 mg (75.0%) of the final desired compound, 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 243-244 ºC. H NMR (300 MHz, CDCl ): d 2.53 (s, 3H), 7.01-7.06 (m, 1H), 7.26- 7.33 (m, 2H), 7.42-7.47 (m. 1H), 7.67 (d, J = 7.0 Hz, 1H), 8.13 (d, J = 7.9 Hz, 1H).
Synthesis of 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 7 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 77.3 mg (62.9%) of the final desired compound, 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 220-222 ºC. H NMR (300 MHz, CDCl ): d 2.65 (s, 3H), 7.07-7.15 (m, 1H), 7.18- 7.26 (m, 2H), 7.50 (d, J = 8.2 Hz, 2H), 8.31 (d, J = 8.2 Hz, 1H), 14.34 (s, 1H).
Synthesis of 2-(3,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (200 mg, 0.40 mml), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 75.7 mg (61.5%) of the final desired compound, 2-(3,5-difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 238-240 ºC. H NMR (300 MHz, CDCl ): d 2.63 (s, 3H), 7.07-7.15 (m, 1H), 7.20- 7.34 (m, 2H), 7.59 (d, J = 8.6 Hz, 1H), 7.77 (dd, J = 8.6, 2.1 Hz, 1H), 8.21 (s, 1H), 14.12 (s, Synthesis of 2-(3,5-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 99.0 mg (78.6%) of the final desired compound, 2-(3,5- difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 207-209 ºC. H NMR (300 MHz, CDCl ): d 7.09-7.17 (m, 1H), 7.20-7.12 (m, 2H), 7.66 (d, J = 8.9 Hz, 1H), 7.91 (dd, J = 8.9, 2.5 Hz, 1H), 8.40 (d, J = 2.5 Hz, 1H), 14.00 (s, 1H).
Synthesis of 2-(3,5-difluorophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (200 mg, 0.35 mmol), diisopropylethylamine (0.121 mL, 0.70 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.066 mL, 0.52 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 91.3 mg (69.2%) of the final desired compound, 2-(3,5- difluorophenyl)carboxybromo-(4H)benzopyranone. m.p. 216-218 ºC. H NMR (300 MHz, CDCl ): d 7.01-7.08 (m, 1H), 7.14-7.18 (m, 2H), 7.51 (d, J = 8.9 Hz, 1H), 7.97 (dd, J = 8.9, 2.3 Hz, 1H), 8.48 (d, J = 2.3 Hz, 1H), 13.60 (s, 1H).
Synthesis of 2-(2,3-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.3-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 68.0 mg (55.3%) of the final desired compound, 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 167-169 ºC. H NMR (300 MHz, CDCl ): d 2.51 (s, 3H), 7.26-7.31 (m, 2H), 7.36- 7.43 (m, 1H), 7.48-7.53 (m, 1H), 7.71 (d, J = 7.3 Hz, 1H), 8.20 (d, J = 7.9 Hz, 1H), 14.21 (s, Synthesis of 2-(2,3-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.3-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 78.0 mg (63.4%) of the final desired compound, 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone.
H NMR (300 MHz, CDCl ): d 2.57 (s, 3H), 7.17-7.27 (m, 3H), 7.42 m.p. 155-156 ºC. 3 (d, J = 8.2 Hz, 2H), 8.24 (d, J = 8.2 Hz, 1H), 14.20 (s, 1H).
Synthesis of 2-(2,3-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.3-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 32.0 mg (26.0%) of the final desired compound, 2-(2,3-difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 120-122 ºC. H NMR (300 MHz, CDCl ): d 2.55 (s, 3H), 7.24-7.30 (m, 2H), 7.35- 7.43 (m, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.69 (dd, J = 8.6, 2.0 Hz, 1H), 8.14 (s, 1H), 14.15 (s, Synthesis of 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 2.3-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 26.0 mg (20.6%) of the final desired compound, 2-(2,3-difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 220 ºC or more. H NMR (300 MHz, CDCl ): d 6.95-7.31 (m, 2H), 7.38-7.46 (m, 1H), 7.69 (dd, J = 8.6, 1.8 Hz, 1H), 7.65 (d, J = 1.8 Hz, 1H), 8.32 (d, J = 8.6 Hz, 1H), 13.85 (s, Synthesis of 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 2.3-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 34.0 mg (27.0%) of the final desired compound, 2-(2,3-difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 120 ºC or more. H NMR (300 MHz, CDCl ): d 7.24-7.32 (m, 2H), 7.38-7.47 (m, 1H), 7.60 (d, J = 8.9 Hz, 1H), 7.84 (dd, J = 8.9, 2.5 Hz, 1H), 8.35 (d, J = 2.5 Hz, 1H), 13.81 (s, Synthesis of 2-(2,3-difluorophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (200 mg, 0.35 mmol), diisopropylethylamine (0.121 mL, 0.70 mmol, 2 eq), 3,5-difluorobenzoyl chloride (0.066 mL, 0.52 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour and 30 minutes, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 90.0 mg (68.2%) of the final desired compound, 2-(2,3-difluorophenyl)carboxybromo-(4H)benzopyranone. m.p. 120 ºC or more. H NMR (300 MHz, CDCl ): d 7.17-7.53 (m, 3H), 7.61 (dd, J = 8.8, 2.3 Hz, 1H), 7.91-7.98 (m, 1H), 8.43 (d, J = 2.3 Hz, 1H), 11.80 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 104.5 mg (85.0%) of the final desired compound, 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 170-172 ºC. H NMR (300 MHz, CDCl ): d 2.54 (s, 3H), 7.20-7.31 (m, 3H), 7.51 (dd, J = 7.6, 7.6 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 8.21 (d, J = 7.6 Hz, 1H), 14.19 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 84.9 mg (69.0%) of the final desired compound, 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 156-158 ºC. H NMR (300 MHz, CDCl ): d 2.59 (s, 3H), 7.15-7.29 (m, 3H), 7.43 (d, J = 8.0 Hz, 2H), 8.12 (d, J = 8.0 Hz, 1H), 14.21 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 2.5-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 82.3 mg (66.9%) of the final desired compound, 2-(2,5- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 120 ºC or more. H NMR (300 MHz, CDCl ): d 2.57 (s, 3H), 7.15-7.30 (m, 3H), 7.52 (d, J = 8.6 Hz, 1H), 7.70 (dd, J = 8.6, 1.9 Hz, 1H), 8.15 (s, 1H), 14.17 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 2.5-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 37.6 mg (29.8%) of the final desired compound, 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 147-150 ºC. H NMR (300 MHz, CDCl ): d 7.26-7.43 (m, 3H), 7.69 (dd, J = 8.6, 1.8 Hz, 1H), 7.75 (d, J = 1.8 Hz, 1H), 8.41 (d, J = 8.6 Hz, 1H), 13.94 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 2.5-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 108.8 mg (86.4%) of the final desired compound, 2-(2,5- difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 168-170 ºC. H NMR (300 MHz, CDCl ): d 7.16-7.33 (m, 3H), 7.60 (d, J = 8.9 Hz, 1H), 7.84 (dd, J = 8.9, 2.5 Hz, 1H), 8.34 (d, J = 2.5 Hz, 1H), 13.77 (s, 1H).
Synthesis of 2-(2,5-difluorophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (200 mg, 0.35 mmol), diisopropylethylamine (0.121 mL, 0.70 mmol, 2 eq), 2,5-difluorobenzoyl chloride (0.066 mL, 0.52 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 15 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 65.2 mg (49.4%) of the final desired compound, 2-(2,5- difluorophenyl)carboxybromo-(4H)benzopyranone. m.p. 152-153 ºC. H NMR (300 MHz, CDCl ): d 7.16-7.32 (m, 3H), 7.53 (d, J = 8.9 Hz, 1H), 7.98 (dd, J = 8.9, 2.3 Hz, 1H), 8.50 (d, J = 2.3 Hz, 1H), 13.77 (s, 1H).
Synthesis of 2-(3,4-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3.4-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 81 mg (66%) of the final desired compound, 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 203-204 ºC. H NMR (300 MHz, CDCl ): d 2.55 (s, 3H), 7.29-7.38 (m, 1H), 7.45- 7.58 (m, 3H), 7.73 (d, J = 6.7 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3,4-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3.4-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 47 mg (38%) of the final desired compound, 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 202-204 ºC. H NMR (300 MHz, CDCl ): d 7.30-7.36 (m, 1H), 7.43 (d, J = 6.9 Hz, 3H), 7.49-7.55 (m, 1H), 8.24 (d, J = 8.7 Hz, 1H), 14.30 (s, 1H).
Synthesis of 2-(3,4-difluorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 3.4-difluorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 70.9 mg (57.6%) of the final desired compound, 2-(3,4- difluorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 222-223 ºC. H NMR (300 MHz, CDCl ): d 2.56 (s, 3H), 7.30-7.36 (m, 1H), 7.42- 7.47 (m, 1H), 7.49-7.56 (m, 2H), 7.70 (dd, J = 8.5, 1.8 Hz, 1H), 8.14 (s, 1H), 14.20 (s, 1H).
Synthesis of 2-(3,4-difluorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 3,4-difluorobenzoyl chloride (0.071 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 10 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 100.8 mg (80.0%) of the final desired compound, 2-(3,4- difluorophenyl)carboxychloro-(4H)benzopyranone. m.p. 195-198 ºC. H NMR (300 MHz, CDCl ): d 7.31-7.37 (m, 1H), 7.43-7.47 (m, 1H), 7.50-7.61 (m, 2H), 7.83 (dd, J = 8.9, 2.4 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H).
Synthesis of 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 4-chlorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (9 mL) for 40 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 99 mg (81%) of the final desired compound, 2-(4-chlorophenyl)- 3-carboxymethyl-(4H)benzopyranone.
H NMR (300 MHz, CDCl ): d 2.53 (s, 3H), 7.46-7.53 (m, 3H), 7.63 m.p. 217-219 ºC. 3 (dd, J = 6.7, 2.0 Hz, 2H), 7.70 (d, J = 6.7 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 14.35 (s, 1H).
Synthesis of 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 4-methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 4-chlorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (9 mL) for 70 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 105 mg (85%) of the final desired compound, 2-(4-chlorophenyl)- 3-carboxymethyl-(4H)benzopyranone. m.p. 220-222 ºC. H NMR (300 MHz, CDCl ): d 2.56 (s, 3H), 7.40 (d, J = 6.7 Hz, 2H), 7.48 (dd, J = 6.7, 2.0 Hz, 2H), 7.60 (dd, J = 6.7, 2.0 Hz, 2H), 8.22 (d, J = 8.6 Hz, 1H), 14.35 (s, 1H).
Synthesis of 2-(4-chlorophenyl)carboxymethyl-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -methylbenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.136 mL, 0.80 mmol, 2 eq), 4-chlorobenzoyl chloride (0.074 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (9 mL) for 60 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 57.0 mg (46.3%) of the final desired compound, 2-(4- chlorophenyl)carboxymethyl-(4H)benzopyranone. m.p. 212-227 ºC. H NMR (300 MHz, CDCl ): d 2.54 (s, 3H), 7.49 (dd, J = 8.6, 2.7 Hz, 3H), 7.60 (dd, J = 8.6, 1.8 Hz, 2H), 7.67 (dd, J = 8.6, 2.1 Hz, 1H), 8.12 (s, 1H), 14.50 (s, Synthesis of 2-(4-chlorophenyl)carboxychloro-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -chlorobenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.131 mL, 0.75 mmol, 2 eq), 4-chlorobenzoyl chloride (0.072 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (9 mL) for 80 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 48.2 mg (38.3%) of the final desired compound, 2-(4- chlorophenyl)carboxychloro-(4H)benzopyranone. m.p. 227-228 ºC. H NMR (300 MHz, CDCl ): d 7.50 (d, J = 8.5 Hz, 2H), 7.55-7.62 (m, 3H), 7.80 (dd, J = 8.9, 2.5 Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 14.20 (s, 1H).
Synthesis of 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- -bromobenzophosphorane compound (200 mg, 0.35 mmol), diisopropylethylamine (0.121 mL, 0.70 mmol, 2 eq), 4-chlorobenzoyl chloride (0.066 mL, 0.52 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 1 hour, and stirred in toluene (9 mL) for 40 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 61.4 mg (46.5%) of the final desired compound, 2-(4- chlorophenyl)carboxybromo-(4H)benzopyranone. m.p. 211-213 ºC. H NMR (300 MHz, CDCl ): d 7.47-7.50 (m, 3H), 7.73 (d, J = 8.5 Hz, 2H), 7.87 (dd, J = 8.8, 2.3 Hz, 1H), 8.39 (d, J = 2.3 Hz, 1H).
Synthesis of 2-(4-chlorophenyl)carboxy-(4H)benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2- hydroxybenzophosphorane compound (200 mg, 0.40 mmol), diisopropylethylamine (0.140 mL, 0.80 mmol, 2 eq), 4-chlorobenzoyl chloride (0.077 mL, 0.60 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 17 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 47.1 mg (38.9%) of the final desired compound, 2-(4- chlorophenyl)carboxy-(4H)benzopyranone. m.p. 212-213 ºC. H NMR (300 MHz, CDCl ): d 7.50 (d, J= 8.6 Hz, 2H), 7.58-7.63 (m, 4H), 7.84-7.90 (m, 1H), 8.35 (dd, J = 8.2, 1.7 Hz, 1H), 14.35 (s, 1H).
Synthesis of 2-(4-chlorophenyl)carboxymethoxy-(4H) benzopyranone Through the general synthesis method of Preparation Example 1 above, a 2-hydroxy- 3-methoxybenzophosphorane compound (200 mg, 0.38 mmol), diisopropylethylamine (0.132 mL, 0.76 mmol, 2 eq), 4-chlorobenzoyl chloride (0.072 mL, 0.57 mmol, 1.5 eq), and 4- (dimethylamino)pyridine (5 mg) were stirred in methylene chloride (4 mL) for 2 hours, and stirred in toluene (9 mL) for 20 hours, and then stirred in TFA (6 mL) and methylene chloride (6 mL) for 2 hours to obtain 30.8 mg (24.4%) of the final desired compound, 2-(4- chlorophenyl)carboxymethoxy-(4H)benzopyranone. m.p. 238-239 ºC. H NMR (300 MHz, CDCl ): d 4.02 (s, 3H), 7.34 (d, J = 8.0 Hz, 1H), 7.49-7.54 (m, 3H), 7.67 (d, J = 8.5 Hz, 2H), 7.88 (dd, J = 8.0, 1.2 Hz, 1H), 14.30 (s, 1H).
Measurement of TNF-induced cell death inhibitory activity of the synthesized 4-benzopyranone derivative compound First, the addition of recombinant TNF to mouse fibroblast LM cells induces cell death, and thus, by using the same, the TNF-neutralization bioassay was constructed. In other words, LM cells were pretreated with TNF (20 ng/ml) and the compounds synthesized in the above examples at various concentrations (5 × 10 cells/well), and a sensitizer actinomycin D (0.5 µg/ml) was added, and cultured in a CO incubator for 24 hours, and then the MTT assay was carried out. At this time, 10 µl of MTT (5 mg/ml stock) was added, reacted for 4 hours, and then dissolved in DMSO to measure the absorbance at 570 nm. First, the TNF cell death inhibition/neutralization action of TNF-target expected compounds at single concentration (50 or 10 µM) was me asured. Second, IC50 values were determined by treating with the compounds having an excellent effect at different concentrations. The % inhibition of TNF was calculated using the following formula: % inhibition of TNF = (OD value of a group treated with TNF and compound - OD value of TNF treated group/(OD value of TNF untreated group - OD value of TNF treated group) × 100.
IC50 values were statistically analyzed using Prism 6 (GraphPad) (IC50: 50% inhibitory concentration, CC50: 50% cytotoxic concentration).
As a result, as disclosed in Tables 1 and 2 below, the cytotoxicity of TNF was inhibited up to 100% when treating with the compounds on the list together in comparison with treating with TNF only.
[Table 1] Compound Concentration (µM) TNF inhibition (%) IC50 (µM) CC50 (µM) Example 1 50 39.1 Example 2 50 46.6 Example 3 50 26.3 Example 4 50 24.6 Example 5 50 34.4 Example 6 50 46.0 Example 7 50 47.0 Example 8 50 24.3 Example 9 50 49.2 Example 10 50 45.6 Example 11 50 60.6 Example 12 50 62.5 Example 13 50 55.9 Example 14 50 38.8 Example 15 50 47.5 Example 16 50 70.2 16.8 > 50 Example 17 50 71.0 2.5 > 50 Example 18 50 48.6 Example 19 50 48.3 Example 20 50 59.0 Example 21 50 55.2 Example 22 50 50.4 Example 23 50 70.1 2.7 > 50 Example 24 50 76.3 2.5 > 50 Example 25 50 41.0 Example 26 50 45.1 Example 27 50 65.2 Example 28 50 34.9 Example 29 50 45.7 Example 30 50 7.4 Example 31 50 24.8 Example 32 50 23.6 Example 33 50 20.7 Example 34 50 21.7 Example 35 50 28.1 Example 36 50 27.0 Example 37 50 33.4 [Table 2] Compound Concentration (µM) TNF inhibition (%) IC50 (µM) CC50 (µM) Example 38 50 30.9 Example 39 50 24.5 Example 40 50 100.0 122.4 > 50 Example 41 50 37.2 Example 42 50 23.0 Example 43 50 19.4 Example 44 50 93.2 45.6 > 50 Example 45 50 88.4 18.5 42.0 Example 46 50 100.0 28.9 > 50 Example 47 50 21.4 Example 48 50 29.0 Example 49 50 37.7 Example 50 50 100.0 5.1 36.0 Example 51 50 100.0 4.5 13.0 Example 52 50 18.5 Example 53 50 22.8 Example 54 50 26.5 Example 55 50 100.0 33.6 25.0 Example 56 50 100.0 16.4 49.0 Example 57 50 100.0 10.3 47.0 Example 58 50 33.8 Example 59 50 32.3 Example 60 50 28.1 Example 61 50 95.7 1.8 > 50 Example 62 50 100.0 3.8 17.0 Example 63 50 100.0 36.9 36.0 Example 64 50 47.2 Example 65 50 25.1 Example 66 50 37.0 Example 67 50 100.0 3.9 21.0 Example 68 50 15.8 Example 69 50 14.6 Example 70 50 28.9 Example 71 50 97.9 3.3 36.0 Example 72 50 100.0 20.8 > 50 Example 73 50 42.0 Example 74 50 79.0 52.5 > 50 Among these compounds, the compound of Example 61 had the lowest IC50 value and cytotoxicity, so that the action mechanism and activity of this compound were studied more in depth. Fig. 1 shows the TNF-inhibiting levels of representative compounds including the compound of Example 61 depending on concentration.
Measurement of TNF direct binding and TNF- etanercept binding inhibitory activity of 4-benzopyranone derivative compounds (1) Measurement of real-time binding of 4-benzopyranone derivative compound to TNF using SPR analysis method The binding kinetics of TNF and 4-benzopyranone derivative compounds was measured by Surface Plasmon Resonance (SPR) method. First, based on the results of pH scouting (10 mM acetate buffer, pH 4.0, 4.5, 5.0, and 5.5), the appropriate buffer pH was determined, and then the recombinant TNF was immobilized on the CM5 chip (4000-5000 RU).
In order to correct an effect of DMSO, a solvent correction standard was then prepared, and DMSO was added to the HBS-EP+ buffer (GE) in an amount of 5%. Then, the 4- benzopyranone derivative compounds were prepared depending on concentration, flowed into the chip (20 µl/min, 500s), and dissolved (500s), and the results of sensorgram were analyzed by a dedicated program to determine the affinity value (K ). At this time, the running buffer was HBS-EP+ buffer (GE), the regeneration buffer was 10 mM glycine (pH 2.5), and Biacore T200 (GE) was used as an analyzer.
As a result, as shown in Fig. 2, the TNF direct binding of the compound of Example 61 was measured using SPR assay, and the binding affinity (K ) was 1.439 × 10 (M) (Figs. 2a and 2b). It was confirmed that the compound of Example 61 did not bind to etanercept (Fig. 2c), and the compound of Example 30, which had almost no TNF neutralization effect (Table 1, 7.4% inhibition), did not bind to TNF (Fig. 2d). (2) Measurement of TNF-etanercept binding inhibitory activity of 4- benzopyranone derivative compounds using SPR analysis method The competition of binding of TNF-inhibiting biopharmaceutical etanercept and the derivative compounds to TNF was measured by SPR assay. Based on the results of pH scouting (10 mM acetate buffer, pH 4.0, 4.5, 5.0, and 5.5), the appropriate buffer pH was determined, and then the recombinant TNF was immobilized on the CM5 chip (4000-5000 RU). In order to correct an effect of DMSO, a solvent correction standard was then prepared, and DMSO was added to the PBST buffer (1 × PBS, pH 7.4, 0.05% Tween 20, 0.01% Triton X-100, 5% DMSO) in an amount of 5%. Then, Etanercept alone or in combination with the compounds was flowed into the chip (20 µl/min, 300s) and dissolved (700s), and the results of sensorgram were analyzed by a dedicated program. The changes in the RU value of the compound mixture samples were observed with comparison with the biopharmaceuticals alone control group. At this time, the running buffer was PBST buffer, the regeneration buffer was 10 mM glycine (pH 2.5), and the instrument was Biacore T200 (GE).
As a result, as shown in Fig. 2e, the compound of Example 61 significantly inhibited the TNF-etanercept binding. Thus, it was proved that the compound and etanercept competed with each other against TNF, and the compound inhibited the binding of TNF to TNF receptor (etanercept) by binding to TNF.
Analysis of TNF-cell binding and TNF-cell signaling inhibitory activity by 4-benzopyranone derivative compounds (1) Measurement of inhibitory activity against binding to Raw 264.7 cell of TNF by 4-benzopyranone derivative compound using flow cytometry analysis method First, macrophage Raw 264.7 cells were prepared (4 × 10 cells/ml), and the biotinylated TNF alone or in combination with the 4-benzopyranone derivative compound (800, 200, 5 µM) was added to the cells and reacted (30 min, 4 ºC). 10 µl of avidin-FITC reagent was then added and reacted in the dark (30 min, 4 ºC). After washing with RDF1 buffer, FACS analysis was carried out (BD Canto). Human TNF-alpha Biotinylated Fluorokine Flow Cytometry Kit (Cat #: NFTA0) of R&D Systems was used in the experiment.
As a result, as shown in Fig. 3a, the compound of Example 61 having the lowest IC50 value (Table 2, 1.8 µM) decreased the target cell binding of TNF to the basal level in a concentration-dependent manner, and the compound of Example 51 having the relatively high IC50 value (Table 2, 4.5 µM) exhibited the moderate inhibitory activity against the TNF-cell binding, and the compound of Example 30 having almost no inhibitory activity against the TNF toxicity (Table 1) did not inhibit the cell binding of TNF at all. Based on the above, it was found that there is a close correlation between the TNF cytotoxicity inhibitory effect and the TNF-cell binding inhibitory effect. (2) Measurement of inhibitory activity against LM cell signaling of TNF by 4- benzopyranone derivative compounds using Western Blot analysis method First, LM cells was treated with TNF alone (50 ng/ml) or a mixture of TNF and the compound of Example 61 (0, 10, 25, 50 µM) for 1 hour, and then the cells were washed and prepared. After the cytoplasmic fraction and nuclear fraction were separated/obtained using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific, cat# 78833), NF-kB p65 protein was detected by SDS-PAGE and Western Blot. Anti-NF-?B p65 rabbit monoclonal antibody (Cell Signaling Technology, cat# D14E12) was used as a primary antibody, and goat anti-rabbit HRP-conjugated antibody (Invitrogen, cat# 656120) was used as a secondary antibody. As a Western Blot control protein (housekeeping protein), GAPDH was used in the cytoplasmic fraction, and Lamin B1 was used in the nuclear fraction. Anti-GAPDH mouse monoclonal antibody (GenScript, cat# A01622) was used as a primary antibody of GAPDH, and goat anti-mouse HRP-conjugated antibody (BETHYLlaboratories, cat# A90-116P) was used as a secondary antibody. Anti-Lamin-B1 rabbit monoclonal antibody (Cell Signaling Technology, cat# 12586S) was used as a primary antibody of Lamin B1, and anti-rabbit HRP- conjugated antibody (Invitrogen, cat# 656120) was used as a secondary antibody.
As a result, as shown in Fig. 3b, it was found that the migration of NF-kB from the cytoplasm to the nucleus activated by the TNF treatment was almost completely inhibited by the treatment of the compound of Example 61 at about 25 µM.
Considering all the results of Fig. 3, the compound of Example 61 also seems to inhibit the cell signaling of TNF by intrinsically blocking the cell binding of TNF.
Analysis of therapeutic effect on sepsis by 4- benzopyranone derivative compounds (1) In vivo TNF neutralization assay (TNF-induced sepsis) Treatment with TNF and a sensitizer D-galactosamine in an in vivo mouse model leads to death from acute liver failure. Thus, the compound of Example 61 (3.3 mpk or 16.5 mpk) was orally administered to BALB/c mice, and after 30 minutes, the mice were IP treated with the mixture of D-galactosamine (21 mg/mouse) and TNF (0.3 µg/mouse). Survival rates were observed and recorded every 3 hours up to 24 hours, and statistically analyzed by log-rank ** *** (Mantel-Cox) test using Prism 6 (GraphPad) (N = 13/group, P < 0.005, P < 0.001). mpk, mg/kg). This confirmed that the in vivo neutralization activity of the compounds binding to TNF in a TNF-induced lethality model.
As a result, as shown in Fig. 4a, it was found that the death of mice due to acute hepatotoxicity induced by D-galactosamine and TNF was inhibited by oral administration (PO) of the compound of Example 61 (3.3, 16.5 mpk) in a concentration-dependent manner. (2) Lipopolysaccharide (LPS)-induced sepsis model The sepsis mouse model was induced by the intraperitoneal infusion of LPS (45 mg/kg; Sigma, E. coli 055:B5). The mouse survival experiment was carried out by observing the survival rates every 24 hours up to 3 days after co-administering the compound of Example 61 (50 mg/kg) and LMT-28 (50 mg/kg) immediately after the infusion of LPS.
As a result, as shown in Fig. 4b, 100% survival rate was shown in the group treated with the compound of Example 61 and LMT-28 in comparison with the LPS alone treated group in which the survival rate was 20% after 72 hours (N = 5/group, P < 0.001).
Analysis of prophylactic/therapeutic effect on rheumatoid arthritis by 4-benzopyranone derivative compounds (1) Prophylactic effect on rheumatoid arthritis (TNF-overexpressing mouse model) The TNF-overexpressing C57BL/6 mouse is a gene recombinant mouse, and a model in which human TNF is overexpressed and arthritis is induced as the age of the mouse becomes higher. The compound of Example 61 (3.3 mpk or 33 mpk) was orally administered to the TNF-overexpressing mice from Week 8 to Week 24, three times a week, and the pathology was measured and recorded from Week 7 to Week 24. The pathology score was measured as 1 = erythema or bent foot, 2 = bent foot and weak swelling, 3 = bent foot and moderate swelling, 4 = ankle bending and weak swelling, 5 = ankle bending and severe swelling (N = 4/group, * P < 0.01, ** P < 0.005, *** P < 0.001).
As a result, as shown in Fig. 5a, the TNF-inhibiting compounds inhibited TNF-induced rheumatoid arthritis in a concentration-dependent manner and showed a significant efficacy even at a low dose of 3.3 mpk. At the dose of 33 mpk, a remarkable prophylactic effect on rheumatoid arthritis was observed in comparison with the negative control group. (2) Therapeutic effect on rheumatoid arthritis (TNF-overexpressing mouse model) First, until the mean level of arthritis of TNF-overexpressing mice reached 8, the mice were raised. As such, etanercept (4.5 mpk), adalimumab (1.2 mpk), the compound of Example 61 (25 mpk, 50 mpk, or 100 mpk) were orally administered to the mice with rheumatoid arthritis from Week 15 to Week 23, three times a week, and the pathology was measured and recorded from Week 7 to Week 23 (N = 5 to 6/group, * P < 0.01, ** P < 0.005, *** P < 0.001).
As a result, as shown in Fig. 5b, the TNF-inhibiting compounds showed a therapeutic on rheumatoid arthritis already induced by TNF in a concentration-dependent manner. efficacy At all doses of 25, 50, and 100 mpk, a remarkable therapeutic effect on rheumatoid arthritis was observed in comparison with the negative control group. When the compound of Example 61 was orally administered at the doses of 50 and 100 mpk, a non-inferior effect was observed even in comparison with adalimumab and etanercept, which are each commercially available injectable biopharmaceuticals. (3) Synergistic therapeutic effect on rheumatoid arthritis when administered in combination with tofacitinib (CIA mouse model) The CIA mouse model is a model in which arthritis is induced by collagen in DBA/1 mice. Thus, a 1:1 mixture of collagen type 2 and CFA was intradermally (ID) injected into the base of the tail of 8-week old DBA/1 mice. Two weeks after the primary immunization, a 1:1 mixture of collagen type 2 and IFA was intradermally (ID) injected into the base of the tail.
After the second immunization, the pathology was measured twice a week, and the groups were divided equally so that the mean of the pathology of each group was 4 points. From Day 35 after the primary immunization, etanercept (4.5 mpk), adalimumab (1.2 mpk), the compound of Example 61 (25 mpk, 50 mpk, or 100 mpk) were orally administered three times a week, and the pathology was measured and recorded. The pathology score was measured as 1 = inflammation and swelling of one toe, 2 = inflammation of one or more toes or weak swelling of the whole sole of the foot, 3 = severe swelling of the whole sole of the foot and swelling of ankle, 4 = very severe inflammation and swelling of the whole foot or the bending and stiffness of foot (N = 7 to 9/group, * P < 0.01, ** P < 0.005, *** P < 0.001).
As a result, as shown in Fig. 5c, the TNF-inhibiting compounds showed remarkable therapeutic efficacy on rheumatoid arthritis already induced by the infusion of collagen. At all doses of 25, 50, and 100 mpk, a remarkable therapeutic effect on rheumatoid arthritis was observed in comparison with the negative control group. The compound of Example 61 (25 mpk) showed considerably similar efficacy to tofacitinib (25 mpk), which is a commercially available oral JAK inhibitor, and showed a non-inferior effect even in comparison with etanercept, which is an injectable biopharmaceuticals. (4) Synergistic therapeutic effect on rheumatoid arthritis when administered in combination with methotrexate (MTX) (CIA mouse model) A 1:1 mixture of collagen type 2 and CFA was intradermally (ID) injected into the base of the tail of DBA/1 mice. Two weeks after the primary immunization, a 1:1 mixture of bovine collagen type 2 and IFA (incomplete Freund's adjuvant) was intradermally (ID) injected into the base of the tail to prepare the rheumatoid arthritis animal model. The thus prepared mice were divided into three groups, i.e., a positive control group (MTX 5 mpk treated group: mice), a group treated with the compound of Example 61 alone (10 mpk treated group: 9 mice), a group treated with MTX and the compound of Example 61 (each 5 mpk and 10 mpk; 9 mice), and a group treated with vehicle (a group treated with 0.05% CMC diluted in distilled water; 15 mice). At the time of the first symptom (Day 25 after the primary immunization), each of the drug was intraperitoneally or orally administered three times a week (license # 201602), and the compound of Example 61 was orally administered once a day.
The severity of arthritis was determined by ascertaining the mean score of arthritis according to the following standard score in the forefoot and hindfoot twice a week from Day 0 to Day 73 after the primary immunization: 0 = normal foot, 1= inflammation and swelling of one toe, 2 = inflammation and swelling of more than one toe, but not all of the toes have inflammation and swelling, or weak swelling of all toes, 3 = inflammation and swelling of all toes, and 4 = severe inflammation and swelling or occlusion of foot.
As a result, as shown in Fig. 8, even when treating with only the compound of Example 61 or MTX alone, the therapeutic effect on arthritis was shown. However, when the two ingredients are used together, the remarkably excellent therapeutic effect on arthritis was shown. Thus, it was confimed that a remarkable synergistic effect was shown.
Analysis of therapeutic effect on inflammatory bowel disease (IBD) by 4-benzopyranone derivative compounds Inflammatory bowel disease was induced by the oral treatment with dextran sodium sulfate (DSS) to mice. The pathology was induced by DSS (2.5%, 6 days) in 7-week old C57BL/6 mice. At the same time, the compound of Example 61 (100 mpk) and metformin (100 mpk) were orally co-administered. After 9 days, the colon length of each treated group was measured, and the therapeutic effect of drugs on inflammatory bowel disease was statistically analyzed (N = 5/group, * P < 0.05, mean ± SEM).
As a result, as shown in Fig. 6, after the TNF inhibitory efficacy was confirmed in experiments in vitro/in vivo using the compound of Example 61, the efficacy against inflammatory bowel disease was analyzed. As a result, it was confirmed that the decrease of the colon length by DSS was significantly inhibited when co-administering the compound of Example 61 and metformin.
Analysis of protective effect on sepsis-induced acute kidney injury by 4-benzopyranone derivative compounds The mice (male, C57/BL6, 12week old, 25-30 g, N = 5) were subjected to cecal ligation and puncture (CLP) or a sham procedure, and then were kept for 48 hours. The compound of Example 61 (50 mpk) was IP infused immediately after the CLP procedure. After 48 hours, in order to measure renal function, the amount of blood urea nitrogen (BUN) and creatinine in serum was analyzed.
As a result, as shown in Fig. 7, the incidence of acute kidney injury (AKI) at 48 hours after the CLP procedure was about 75%, whereas in case of the compound treated group, there was no significant increase or there was a slight increase in the kidney injury marker in all of the treated groups.
While the present invention has been particularly described with reference to specific embodiments thereof, it will be apparent to those skilled in the art that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. That is, the practical scope of the present invention is defined by the appended claims and equivalents thereof.
Claims (7)
1. A pharmaceutical composition for preventing or treating TNF overexpression diseases, characterized in that the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock, and the pharmaceutical composition comprises a 4-benzopyranone derivative represented by Formula 1 or its pharmaceutically acceptable salt as an active ingredient, and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF): in which, R is furanyl, thiophenyl, or substituted phenyl represented by 7 8 9 10 11 R , R , R , R , and R are each independently hydrogen, chloro, bromo, fluoro, or methoxy; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
2. The pharmaceutical composition for preventing or treating TNF overexpression diseases as claimed in claim 1, characterized in that the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock, and the pharmaceutical composition comprises the 4-benzopyranone derivative selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2-thiophenyl) carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H) benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy chloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H) benzopyranone; 2-(3,4-dimethoxyphenyl)carboxybromo-(4H)benzopyranone; 2- (3,4-dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxy-(4H)benzopyranone; 2-(3-fluorophenyl)carboxychloro-(4H) benzopyranone; 2-(3-fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3- fluorophenyl)carboxybromo-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy methoxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy-(4H)benzopyranone; 2- (3,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,5-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
3. The pharmaceutical composition for preventing or treating TNF overexpression diseases as claimed in claim 1, characterized in that the composition comprises 4- benzopyranone derivative and a drug as an active ingredient; the 4-benzopyranone derivative is any one selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro- (4H)benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2-thiophenyl) carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H) benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxy-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxy chloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H) benzopyranone; 2-(3,4-dimethoxyphenyl)carboxybromo-(4H)benzopyranone; 2- (3,4-dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxy-(4H)benzopyranone; 2-(3-fluorophenyl)carboxychloro-(4H) benzopyranone; 2-(3-fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3- fluorophenyl)carboxybromo-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy methoxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy-(4H)benzopyranone;; 2-(3,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(2,5-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,5-difluorophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4- difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxy chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone; and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF); the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock.
4. The pharmaceutical composition for preventing or treating TNF overexpression diseases according to claim 3, characterized in that the drug is selected from the group consisting of methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, bucillamine, cyclosporine, tacrolimus, azathioprine, cyclophosphamide, mizoribine, penicillamine, oral gold preparation, antimalarial agent, 6-mercaptopurine, indomethacin, naproxen, sulindac, diclofenac, aceclofenac, mefenamic acid, aspirin, fenoprofen, salsalate, piroxicam, etodolac, flurbiprofen, ibuprofen, loxoprofen, nabumetone, lonazolac, meloxicam, fenbufen, ketorolac tromethamine, indoprofen, ketoprofen, suprofen, carprofen, tiaprofenic acid, flufenamic acid, ebselen, felbinac, tolmetin, flunixin, celecoxib, rofecoxib, hydrocortisone, cortisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, fludrocortisone, entocort, 5-aminosalicylate, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine, mechlorethamine, thiotepa, chlorambucil, melphalan, carmustine, lomustine, busulfan, sestrin 2, withaferin A, celastrol, quercetin, luteolin, curcumin, metformin, dibromomannitol, GR270773, pentoxifylline, N-acetylcysteine, melatonin, resveratrol, mesalamine, single chain fatty acid, glutamine, gemfibrozil, retinoid, hydroxyurea, trihydroxyisoflavone, deoxykaempferol, kaempferol, gingerol, caffeic acid, cyanidin, cryptotanshinone, deguelin, delphinidin, equol, fisetin, myricetin, procyanidin B2, metronidazole, ciprofloxacin, niclosamide, thiabendazole, imipenem-cilastatin, fluoroquinolone, tofacitinib, glyburide, rolipram, doxycycline, VX-166, zVAD, L1, ISO- 1, tauroursodeoxycholic acid, HK-156, A-285222, CP-0127, Bis-N-norgliovictin, aurintricarboxylic acid, chloroamidine, ouabain, terazosin, prazosin, tranilast, apremilast, monobenzone, phenazopyridine, 546C88, NOX-100, gabexate mesilate, ulinastatin, somatostatin, octreotide, IKK inhibitor, caspase inhibitor, TAK-242, eritoran, ki16425, camptothecin, caffeic acid phenethyl ester, sulforaphane, Tim-3, BN-52021, BB-882, TCV- 309, CT-400, ethyl pyruvate, hemin, CORM-2, tanshinone IIA sulfonate, nicotine, EGCG, isorhamnetinO-galactoside, persicarin, catechin, carbenoxolone, glycyrrhizin, emodinO- b-D-glucoside, acteoside, forsythoside B, rosmarinic acid, chlorogenic acid, inflachromene, cilostazol, clopidogrel, sarpogrelate, drotrecogin alpha, carbamazepine, chloroquine, anakinra, tocilizumab, LMT-28, 1-(3-dimethylaminopropyl)ethylurea, gp130Fc, beta-arrestin 2, IL- 30, diacerein, secukinumab, ustekinumab, ixekizumab, thalidomide, adalimumab, infliximab, pravastatin, atorvastatin, rosuvastatin, simvastatin, losartan, telmisartan, hydrochlorothiazide, furosemide, propranolol, metoprolol, captopril, amlodipine, clonidine, methyldopa, minoxidil, streptozotocin, mitomycin, cisplatin, daunorubicin, doxorubicin, dactinomycin, bleomycin, mithramycin, anthramycin, calicheamicin, duocarmycin, vincristine, taxol, docetaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vinblastine, colchicine, dihydroxy anthracenedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, procaine, tetracaine, lidocaine, propranolol, tamoxifen, bazedoxifene, puromycin, anetholtrithion, nivolumab, pembrolizumab, ipilimumab, atezolizumab, alpha- galactosylceramide, SRT3025, DTA-1, IL-7, IL-2, IL-15, CXCL1, ATRA, gemcitabine, carboplatin, NCX-4016, CDDO-Me, sunitinib, zoledronic acid, Astragalus polysaccharide, rituximab, imuran, abatacept, GW9662, rosiglitazone, Y-27632, and alefacept.
5. A health functional food composition for preventing or alleviating TNF overexpression diseases, characterized in that the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock, and the health functional food composition comprises a 4-benzopyranone derivative represented by Formula 1 or its pharmaceutically acceptable salt as an active ingredient, and inhibits a TNF activity by being directly bound to tumor necrosis factor (TNF): in which, R is furanyl, thiophenyl, or substituted phenyl represented by , 7 8 9 10 11 R , R , R , R , and R are each independently hydrogen, chloro, bromo, fluoro, or methoxy; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
6. The health functional food composition for preventing or alleviating TNF overexpression diseases as claimed in claim 5, characterized in that the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock, and the health functional food composition comprises the 4-benzopyranone derivative selected from the group consisting of 2-(2-chlorophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-chlorophenyl) carboxy-(4H)benzopyranone; 2-(2-furanyl)carboxy-(4H)benzopyranone; 2-(2- furanyl)carboxymethoxy-(4H)benzopyranone; 2-(2-furanyl)carboxymethoxy- (4H)benzopyranone; 2-(2-furanyl)carboxymethoxy-(4H)benzopyranone;; 2-(2- furanyl)carboxychloro-(4H)benzopyranone; 2-(2-furanyl)carboxychloro-(4H)- 4-benzopyranone; 2-(2-furanyl)carboxybromo-(4H)benzopyranone; 2-(2- thiophenyl)carboxymethoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxy methoxy-(4H)benzopyranone; 2-(2-thiophenyl)carboxymethoxy-(4H) benzopyranone; 2-(2-thiophenyl)carboxy-(4H)benzopyranone; 2-(2-thiophenyl) carboxychloro-(4H)benzopyranone; 2-(2-thiophenyl)carboxychloro-(4H) benzopyranone; 2-(2-thiophenyl)carboxybromo-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxy-(4H)benzopyranone;; 2-(3,4-dimethoxyphenyl)carboxy- 7-chloro-(4H)benzopyranone; 2-(3,4-dimethoxyphenyl)carboxychloro-(4H) benzopyranone; 2-(3,4-dimethoxyphenyl)carboxybromo-(4H)benzopyranone; 2- (3,4-dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3,4- dimethoxyphenyl)carboxymethoxy-(4H)benzopyranone; 2-(3-fluorophenyl) carboxy-(4H)benzopyranone;; 2-(3-fluorophenyl)carboxychloro-(4H) benzopyranone; 2-(3-fluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3- fluorophenyl)carboxybromo-(4H)benzopyranone; 2-(3-fluorophenyl)carboxy methoxy-(4H)benzopyranone; 2-(3,5-difluorophenyl)carboxy-(4H)benzopyranone; 2- (3,5-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(3,5-difluorophenyl) carboxybromo-(4H)benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,3-difluorophenyl)carboxychloro-(4H)benzopyranone; 2-(2,3- difluorophenyl)carboxybromo-(4H)benzopyranone;; 2-(2,5-difluorophenyl) carboxychloro-(4H)benzopyranone; 2-(2,5-difluorophenyl)carboxychloro-(4H) benzopyranone; 2-(2,5-difluorophenyl)carboxybromo-(4H)benzopyranone;; 2-(3,4- difluorophenyl)carboxychloro-(4H)benzopyranone;; 2-(4-chlorophenyl)carboxy- 6-chloro-(4H)benzopyranone; 2-(4-chlorophenyl)carboxybromo-(4H) benzopyranone; 2-(4-chlorophenyl)carboxy-(4H)benzopyranone; and 2-(4-chlorophenyl)carboxymethoxy-(4H)benzopyranone.
7. A reagent composition for inhibiting a TNF activity in vitro, comprising a 4- benzopyranone derivative represented by Formula 1 or its pharmaceutically acceptable salt as an active ingredient: in which, R is furanyl, thiophenyl, or substituted phenyl represented by, 7 8 9 10 11 R , R , R , R , and R are each independently hydrogen, chloro, bromo, fluoro, or methoxy; R is hydrogen or lower alkyl of (C1-C4); and 3 4 5 6 R , R , R , and R are each independently hydrogen, halogen, or (C1-C4)alkoxy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170135899A KR101934651B1 (en) | 2017-10-19 | 2017-10-19 | Composition for Preventing or Treating TNF-mediated Disease Comprising Novel Derivatives and Method for Inhibiting TNF-activity with the Same |
PCT/KR2018/007922 WO2019078452A1 (en) | 2017-10-19 | 2018-07-12 | Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ763267A NZ763267A (en) | 2023-08-25 |
NZ763267B2 true NZ763267B2 (en) | 2023-11-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11850230B2 (en) | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | |
KR101982667B1 (en) | Composition for Preventing or Treating TNF-mediated Disease Comprising Novel Derivatives and Method for Inhibiting TNF-activity with the Same | |
CA2917344C (en) | Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds | |
WO2023032987A1 (en) | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof | |
JP2021529186A (en) | NLRP regulator | |
JP2006526614A (en) | 3-Arylsulfanyl and 3-heteroarylsulfanyl-substituted benzo [b] thiophenes as therapeutic agents | |
JP6909236B2 (en) | Quinazoline derivative or salt thereof and a pharmaceutical composition containing it | |
CN108069942A (en) | Phthalide pyrazolone conjugate, preparation method and use | |
RU2788739C2 (en) | Composition for the prevention or treatment of tnf-related diseases containing a new derivative as an active ingredient and a method for inhibiting tnf activity with its help | |
NZ763267B2 (en) | Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same | |
US9296690B2 (en) | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | |
JP2022506891A (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
WO2016116942A1 (en) | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin | |
JP2024147607A (en) | Composition for preventing or treating TNF-related diseases containing a novel derivative as an active ingredient and method for inhibiting TNF activity using the same | |
KR102105483B1 (en) | Composition for preventing or treating TNF-mediated diseases comprising tetrahydropapaverine and IL-6 inhibitor, and method for inhibiting TNF-activity with the same | |
JP7185226B2 (en) | AMPK Activator Containing 1,5-Anhydrofructose Derivative | |
US11629121B2 (en) | Benzylideneacetone derivative and use thereof | |
US20190328694A1 (en) | Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient | |
KR20190012556A (en) | Novel benzylideneacetone derivatives and uses thereof | |
KR102241064B1 (en) | Novel indole derivatives and composition for preventing or treating inflammatory diseases comprising the same | |
WO2024177126A1 (en) | 6-alkoxypyrazolopyrimidine compound and pharmaceutical use thereof | |
KR20210048208A (en) | Composition for preventing or treating TNF-mediated diseases comprising tetrahydropapaverine and method for inhibiting TNF-activity with the same | |
KR20210155806A (en) | Polymorphism of PI3K inhibitor and method for preparing same | |
KR20210098689A (en) | Substituted arylurea compounds for inducing apoptosis and composition for anticancer comprising the same | |
KR101551187B1 (en) | Indazole derivatives selectively inhibiting the activity of Janus kinase 1 |